Table of Contents

• Trial overview
• Who is being studied
• What the study is measuring
• Study design and treatment groups
• Trial status and size

Trial overview

One authorised Phase 1/2 study is investigating ALN-4324 in people who are overweight to obese, including healthy volunteers and patients with type 2 diabetes mellitus (T2DM).^[1] The study is interventional, which means the research team gives a study treatment and then measures the results.^[1]

Who is being studied

The trial title says it includes overweight to obese healthy volunteers and overweight to obese patients with T2DM.^[1] This means the study is not limited to one group; it is looking at both people without diabetes and people with diabetes in the same weight range.^[1]

The condition listed for the study is type 2 diabetes mellitus.^[1] T2DM is a long-term condition in which the body does not use insulin properly, leading to high blood sugar.

What the study is measuring

The main outcome is the frequency of adverse events, also called AEs.^[1] Adverse events are unwanted medical events that happen during a study, whether or not they are caused by the treatment.

The study also checks safety through vital signs, ECGs, and clinical laboratory assessments.^[1] Vital signs are basic body measurements such as blood pressure and pulse. An ECG is a test that records the heart’s electrical activity.

The brief summary says the study aims to evaluate the safety and tolerability of multiple doses of ALN-4324 in patients with T2DM.^[1] Tolerability means how well people handle the treatment and whether it causes problems that are difficult to accept.

Study design and treatment groups

The trial compares ALN-4324 given subcutaneously with phosphate buffered saline for subcutaneous administration.^[1] Subcutaneous means given under the skin.

The source data does not give detailed participant rules, dose amounts, or the exact schedule of visits.^[1] It does show that the study is focused on early safety evaluation rather than late-stage treatment testing.^[1]

Trial status and size

The trial status is listed as Authorised.^[1] The planned enrolment is 60 people.^[1] Enrolment means the number of participants planned for the study.

Table of Contents

• What is Eneboparatide?
• How Does Eneboparatide Work?
• What Condition Does Eneboparatide Treat?
• Clinical Trial Information
• Potential Benefits
• Administration and Dosage
• Eligibility for Treatment
• Safety Considerations

What is Eneboparatide?

Eneboparatide, also known as AZP-3601, is a new medication being developed to treat chronic hypoparathyroidism^[1]. It is classified as a parathyroid hormone receptor agonist, which means it works by mimicking the action of parathyroid hormone in the body^[2].

How Does Eneboparatide Work?

Eneboparatide is designed to activate the parathyroid hormone receptor, which plays a crucial role in regulating calcium levels in the body. By doing so, it aims to help maintain normal calcium levels in patients with chronic hypoparathyroidism, potentially reducing the need for high doses of calcium and vitamin D supplements^[3].

What Condition Does Eneboparatide Treat?

Eneboparatide is being developed to treat chronic hypoparathyroidism. This is a rare condition where the body doesn’t produce enough parathyroid hormone, leading to low calcium levels and various symptoms. Patients with this condition often require lifelong treatment with calcium and vitamin D supplements^[4].

Clinical Trial Information

Eneboparatide is currently being studied in a Phase 3 clinical trial called CALYPSO. This is an advanced stage of research that aims to confirm the effectiveness and safety of the drug^[5]. The trial is:

• Multicenter: Conducted at multiple hospitals or research centers
• Randomized: Participants are randomly assigned to receive either eneboparatide or a placebo
• Placebo-controlled: Some participants receive an inactive substance for comparison
• Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or placebo

Potential Benefits

The main goals of the eneboparatide treatment being studied are^[6]:

• To eliminate the need for active vitamin D supplements
• To reduce the need for high doses of calcium supplements (aiming for 600 mg/day or less)
• To maintain normal blood calcium levels
• To improve physical and cognitive symptoms associated with hypoparathyroidism
• To enhance overall quality of life for patients

Administration and Dosage

Eneboparatide is administered as a subcutaneous injection, which means it’s injected under the skin. It comes in a pre-filled injection pen, making it potentially easier for patients to self-administer at home^[7]. The maximum daily dose being studied is 100 micrograms, but the optimal dose may vary for each patient^[8].

Eligibility for Treatment

While eneboparatide is still in clinical trials, the study includes adult patients aged 18 to 80 years who have had chronic hypoparathyroidism for at least 12 months. Patients must also be currently taking calcium and vitamin D supplements to manage their condition^[9].

Safety Considerations

As with any medication, there are potential safety considerations. The clinical trial excludes patients with certain conditions or medical histories, such as:

• Recent history of certain cancers
• Severe kidney problems
• Certain heart conditions
• History of bone cancer (osteosarcoma)

It’s important to note that the full safety profile of eneboparatide is still being studied^[10].

Table of Contents

• Overview of the studies
• Who the trials include
• What the trials measure
• Trial phases and status
• Study details by trial
• What the results could show

Overview of the studies

These clinical trials are studying ZILUCOPLAN in people with generalized myasthenia gravis (gMG), a disease that causes muscle weakness in several parts of the body.^[1][2]

The available trials focus on later stages of research, with Phase 3 and Phase 4 studies listed in the source data.^[1][2]

Across the trials, researchers are mainly looking at safety, long-term tolerability, and in some studies how ZILUCOPLAN behaves in the body and how it affects disease-related tests.^[1][2]

Who the trials include

One trial is for pediatric participants, meaning children and adolescents, and it includes patients from 2 to under 18 years of age with gMG.^[2]

Another pediatric study follows children who already took part in a previous ZILUCOPLAN study, so it is designed as a follow-up for earlier participants.^[1]

The adult extension study includes people with gMG who have already completed a qualifying ZILUCOPLAN clinical study.^[3]

One additional study listed in the data is a broader myasthenia gravis study that includes ZILUCOPLAN among many other treatments, but its main focus is not ZILUCOPLAN alone.^[4]

What the trials measure

The pediatric long-term safety study measures treatment-emergent adverse events (health problems that appear after treatment starts), serious adverse events, treatment stopping because of side effects, and infections.^[1]

The pediatric Phase 4 study measures plasma concentrations of ZILUCOPLAN, which means how much of the study drug is found in the blood, at Week 4.^[2]

That same study also measures change from baseline in sheep red blood cell (sRBC) lysis and complement component 5 (C5) levels at Week 4, which are laboratory tests used in the study to track biological effects.^[2]

The adult extension study measures the incidence of TEAEs, which helps show how often new side effects happen during follow-up treatment.^[3]

The broader study that lists ZILUCOPLAN among several treatments measures MG-ADL and QMG changes at 24 weeks in different phases, which are scores used to track daily function and muscle weakness in myasthenia gravis.^[4]

Trial phases and status

The pediatric safety follow-up study is in Phase 3 and is marked Authorised with an enrollment of 10 participants.^[1]

The pediatric study of blood levels and biological effects is in Phase 4, also marked Authorised, with an enrollment of 10 participants.^[2]

The adult long-term extension study is in Phase 3, is Authorised, and has a planned enrollment of 190 participants.^[3]

The broader study that includes ZILUCOPLAN alongside other treatments is listed as Phase 4, Authorised, with 66 participants.^[4]

Study details by trial

NCT06435312 is a long-term safety study in children with gMG who already joined a previous ZILUCOPLAN study.^[1] The brief summary says it is designed to assess safety and tolerability over an extra 52 weeks of daily subcutaneous treatment.^[1]

NCT06055959 studies how ZILUCOPLAN moves through the body over time and how safe it is in children with gMG.^[2] Its brief summary also says it looks at both pharmacokinetics and pharmacodynamics, which means it studies drug levels in the body and the body’s response to treatment.^[2]

NCT04225871 is an adult extension study that looks at long-term safety and tolerability in people with gMG who finished a qualifying ZILUCOPLAN study.^[3] Its only listed primary outcome is the incidence of TEAEs.^[3]

NCT06193889 is a broader study of anti-CD19 chimeric antigen receptor T-cell therapy in generalized myasthenia gravis, and it lists ZILUCOPLAN among several study drugs.^[4] Its primary outcomes in the source data focus on safety, MG-ADL change, and QMG change at 24 weeks for the main study treatment being tested.^[4]

What the results could show

These trials may help show whether ZILUCOPLAN can be used safely over time in children and adults with generalized myasthenia gravis.^[1][3]

They may also help researchers understand whether the treatment reaches the blood in expected amounts and whether it changes study markers linked to disease activity.^[2]

Because the studies are in later phases, they are especially focused on real patient experience, follow-up safety, and longer-term observation rather than early proof-of-concept testing.^[1][2][3]

Table of Contents

• Clinical trials overview
• Conditions being studied
• Trial designs and phases
• What the trials measure
• Who may take part
• Long-term follow-up studies
• Summary of the main trials

Clinical trials overview

The trial data show that Vosoritide is being studied in children with several growth conditions, which are health conditions linked to short height or slower growth.^[1] The studies are looking at both safety and possible benefit for growth, which means researchers want to know whether the treatment can be used over time and whether it may help children grow better.^[1][2]

These trials include children with achondroplasia, hypochondroplasia, Turner syndrome, short stature homeobox-containing gene deficiency, Noonan syndrome, and idiopathic short stature.^[1][2][3][4]

Conditions being studied

Achondroplasia is studied in two trials, including a long-term study in children and a later comparison study against BMN 333.^[1][5]

Hypochondroplasia is studied in three trials: one Phase 3 study in children, one Phase 2 study in infants and young children aged 0 to less than 36 months, and one long-term extension study.^[2][3][4]

Two other trials study children with Turner syndrome, short stature homeobox-containing gene deficiency, and Noonan syndrome, or children with idiopathic short stature.^[6][7]

Trial designs and phases

The studies use different trial designs, including randomized, double-blind, and placebo-controlled designs.^{[2][3][6] Randomized means children are put into groups by chance. Double-blind means neither the family nor the study team knows who gets which treatment during the trial. Placebo-controlled means some participants receive a look-alike treatment with no active study drug, so results can be compared fairly.}

The trial phases range from Phase 2 to Phase 4.^{[1][2][4][5][6][7][8]} Phase 2 trials in this set look at early safety and growth effects, while Phase 3 trials test the treatment in larger groups and Phase 4 studies look at later comparisons or follow-up.^[2][4][5][8]

What the trials measure

The main growth outcome in several studies is annualized growth velocity (AGV), which means how much a child grows in one year.^{[2][3][6][7][8] Some trials measure change from baseline, which means they compare results with the starting point before treatment began.[2][3][6][7][8]}

Other important outcomes include height Z-score, height, and the upper-to-lower body segment ratio.^{[3][4][5] The height Z-score shows how a child’s height compares with other children of the same age and sex. The upper-to-lower body segment ratio helps researchers understand body proportions, which is important in some growth conditions.}

Safety outcomes are also important. Researchers track adverse events, serious adverse events, laboratory tests, vital signs, physical examination findings, electrocardiograms, echocardiograms, imaging, and clinical hip assessment in some studies.^{[1][3][5] Adverse events are unwanted medical problems that happen during a study, and serious adverse events are more serious problems that may need special care.}

Who may take part

The studies are designed for children, not adults, and the age groups vary by trial.^{[1][3][6][7] One hypochondroplasia study includes infants and young children from birth to under 36 months.[3] Other studies include children with specific growth conditions such as achondroplasia, Turner syndrome, SHOX deficiency, Noonan syndrome, or idiopathic short stature.[1][2][5][6][7]}

Some trials compare Vosoritide with placebo, while others compare it with another treatment approach or continue treatment over a longer time.^{[2][3][4][6][7][8]}

Long-term follow-up studies

Several trials are long-term extension studies, which means they follow children after the first part of the study ends.^{[1][4][5] These studies are important because they look at treatment effects over time, including until final adult height, which is the height a person reaches when growth is finished.[4]}

The long-term studies in achondroplasia and hypochondroplasia track both growth and safety, including treatment-emergent adverse events and yearly changes in height measures.^[1][4][5]

Summary of the main trials

The completed trials include a Phase 2 study in achondroplasia and a Phase 3 study in hypochondroplasia.^{[1][2] The authorised trials include Phase 2 and Phase 3 studies in hypochondroplasia, a Phase 3 extension study in achondroplasia, a Phase 2 basket study in Turner syndrome, SHOX deficiency, and Noonan syndrome, a Phase 2 study in idiopathic short stature, and a Phase 4 comparison study in achondroplasia.[3][4][5][6][7][8]}

Across the studies, the main research questions are whether Vosoritide can improve growth, how its effects compare with placebo or other treatments, and how safe and tolerable it is during short-term and long-term use.^{[1][2][3][4][5][6][7][8]}

Table of Contents

• Clinical trial overview
• Kidney transplant study
• Type 2 diabetes studies
• Other trial use
• Main endpoints and what they mean
• Who the studies are for

Clinical trial overview

The trial data show that Vildagliptin is being studied in interventional clinical trials, which means researchers give a treatment and measure the results.^[1] The listed studies are in Phase 2 and Phase 3, which are stages used to test how well a treatment works in people and to collect more safety and outcome data.^[1][2]

Kidney transplant study

The PRODIG study, NCT02849899, is a Phase 3 trial in people after renal transplant, which means kidney transplant.^[1] It is authorised and plans to enroll 186 participants.^[1]

This study is testing whether a short-term course of Vildagliptin in the early post-transplant period can prevent new onset diabetes after transplantation, meaning diabetes that starts after the transplant.^[1] The main result is the proportion of patients who have diabetes 1 year after transplantation, based on diabetes treatment use, fasting glucose above 7 mmol/L, or an abnormal oral glucose tolerance test (OGTT).^[1]

Type 2 diabetes studies

One authorised Phase 3 study, 2025-520686-46-00, is in adults with Type 2 Diabetes Mellitus and plans to enroll 504 participants.^[2] It is studying whether treatment guided by genetics, called pharmacogenetic-guided treatment, works better than optimized standard treatment for people whose diabetes is not well controlled.^[2]

In this study, Vildagliptin appears among the treatment options used in the trial plan.^[2] The main endpoint is the proportion of patients who reach HbA1c ≤7% at Week 24 in the experimental arm compared with the control arm.^[2]

Another large Phase 3 study, NCT05433584, is also in adults with Type 2 Diabetes and has an enrollment of 781 participants.^[4] Vildagliptin is listed among many treatment options in this study, which compares tirzepatide with intensified conventional care.^[4] The main endpoint is change from baseline in HbA1c, a blood test that shows average blood sugar over time.^[4]

Other trial use

A completed Phase 2 study, 2024-511295-33-00, looked at people with advanced breast cancer treated with alpelisib plus endocrine therapy.^[3] Vildagliptin was listed among the trial treatments, along with other medicines used in the study.^[3]

This trial focused on hyperglycemia, which means high blood sugar, during the first 8 weeks of alpelisib treatment.^[3] One main endpoint was the rate of grade 3-4 hyperglycemia in cohorts A and B, and another was permanent discontinuation of alpelisib due to related adverse events in cohort C.^[3]

Main endpoints and what they mean

Clinical trials use endpoints, which are the main results they want to measure.^[1][2][3][4]

• Diabetes prevention after transplant: the study checks how many patients have diabetes 1 year after kidney transplantation.^[1]

• HbA1c target: the study checks how many people reach HbA1c ≤7% at Week 24.^[2]

• Change in HbA1c: the study measures how blood sugar control changes from the start of the study to later time points.^[4]

• Hyperglycemia during cancer treatment: the study measures how often severe high blood sugar happens in the first 8 weeks.^[3]

Who the studies are for

The trial data show that Vildagliptin is being studied in different patient groups, not just one disease area.^[1][2][3][4]

• People after kidney transplant, where the study asks if early treatment can lower later diabetes risk.^[1]

• Adults with type 2 diabetes, where the study looks at better blood sugar control with tailored treatment.^[2]

• People in a cancer treatment setting, where the study examined blood sugar problems during alpelisib therapy.^[3]

Table of Contents

• Clinical trials overview
• Type 1 diabetes studies
• Heart disease and rhythm studies
• Other pediatric study
• Outcomes and endpoints
• Study designs and participants

Clinical trials overview

The trials in this set study Verapamil in several different patient groups, including people with type 1 diabetes, hypertrophic cardiomyopathy, ventricular fibrillation, frequent premature ventricular complexes, and tuberous sclerosis complex.^{[1][2][3][4][5]}

Across these studies, Verapamil is being tested in different ways: alone, compared with placebo, and compared with other active drugs.^{[1][2][3][4][5]}

Type 1 diabetes studies

One Phase 2 study, Image-VER-A-T1D, includes adults with type 1 diabetes and has 30 planned participants.^[1] It compares treatment with Verapamil and EXENATIDE against a placebo group, and the main goal is to measure pancreatic uptake on PET/CT as a way to estimate beta cell mass before and after treatment.^[1]

Another study is a Phase 1 trial in children with recent-onset type 1 diabetes, with 36 planned participants.^[3] This double-blind, randomized, placebo-controlled study looks at whether oral Verapamil can help preserve residual insulin secretion, which means the amount of insulin the body still makes after diagnosis.^[3]

The main safety endpoint in part A is the frequency of adverse events and serious adverse events during treatment, while part B measures change in C-peptide during a mixed meal tolerance test at month 24.^[3]

Heart disease and rhythm studies

One Phase 3 study in 140 patients examines Verapamil in symptomatic people with non-obstructive hypertrophic cardiomyopathy.^[2] The study aims to reduce symptoms and arrhythmic complications, and it measures changes in VO2 max, left ventricular end-diastolic volume, and the incidence of non-sustained ventricular tachycardia.^[2]

Another Phase 2 pilot trial compares Verapamil with QUINIDINE in short-coupled idiopathic ventricular fibrillation.^[4] This open-label, randomized crossover study has 24 planned participants and looks at sustained ventricular arrhythmia using a severity scoring system.^[4]

A larger low-intervention study called SUPPRESS includes asymptomatic patients with frequent PVCs and normal LVEF, with 298 planned participants.^[5] It tests whether preventive treatment, including Verapamil and other drugs, can lower the risk of later left ventricular dysfunction within 2 years.^[5]

Other pediatric study

One Phase 2 study in 64 children under 4 months of age with tuberous sclerosis complex includes Verapamil among several treatment options.^[6] The study compares treatment strategies with standard of care alone and measures neuropsychologic outcome at 24 months using Bayley Scales of Infant and Toddler Development III testing.^[6]

Outcomes and endpoints

The main endpoints differ by disease area, but they all focus on measurable signs of benefit or harm.^{[1][2][3][4][5][6]}

• In diabetes studies, the main outcomes look at pancreatic imaging, beta cell mass, and C-peptide, which help show how much insulin-making function remains.^[1][3]

• In heart studies, the outcomes include exercise capacity, heart chamber size, arrhythmia events, and left ventricular function, which show how well the heart is working.^[2][4][5]

• In the pediatric neurodevelopment study, the outcome is cognitive testing at 24 months, which checks early brain development and learning skills.^[6]

Study designs and participants

The studies use several common research designs, including interventional trials, randomized trials, placebo-controlled trials, and crossover studies.^[1][3][4]

Participants vary by trial: some studies enroll adults, some enroll children, and some focus on people with no symptoms but a specific heart rhythm finding.^[1][3][5][6]

Trial phases also vary, from Phase 1 safety and early testing to Phase 3 larger confirmatory research, showing that Verapamil is being studied at different stages of development for different conditions.^[2][3][4]

Table of Contents

• What is PLS240?
• What condition does PLS240 treat?
• How PLS240 works
• Administration and dosage
• Clinical trials
• Potential benefits
• Safety and side effects
• Who may be eligible for PLS240 treatment?

What is PLS240?

PLS240 is the study name for a new medication called upacicalcet sodium hydrate. It is being developed as a potential treatment for a condition called secondary hyperparathyroidism in people with advanced kidney disease.^[1]

What condition does PLS240 treat?

PLS240 is being studied to treat secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease (ESKD) who are on hemodialysis. Secondary hyperparathyroidism is a common complication in people with kidney failure. It occurs when the parathyroid glands produce too much parathyroid hormone (PTH) in response to low calcium levels in the blood.^[2]

In ESKD, the kidneys can no longer effectively filter waste products from the blood or maintain proper levels of important minerals like calcium and phosphorus. This leads to mineral imbalances that cause the parathyroid glands to become overactive.

How PLS240 works

PLS240 is designed to help control PTH levels in patients with SHPT. While the exact mechanism is not fully described in the trial information, medications for SHPT typically work by mimicking calcium’s effects on the parathyroid glands. This tricks the glands into reducing PTH production.^[3]

Administration and dosage

PLS240 is given as an intravenous injection three times per week after dialysis sessions. The dose is adjusted based on the patient’s PTH and calcium levels. The maximum daily dose being studied is 300 micrograms.^[4]

The medication comes in pre-filled syringes called Poolsep II, which are manufactured by Nipro Corporation in Japan.^[5]

Clinical trials

PLS240 is currently being studied in Phase 3 clinical trials called PATH-1 and PATH-2. These are large studies designed to evaluate how well the medication works and how safe it is in patients with SHPT who are on hemodialysis.^[6]

The trials have two main parts:

1. A double-blind phase lasting 27 weeks, where patients receive either PLS240 or a placebo
2. An open-label extension phase, where all patients receive PLS240 for additional safety monitoring

Potential benefits

The main goals of the PLS240 clinical trials are to see if the medication can:^[7]

• Reduce PTH levels by 30% or more in patients
• Help patients achieve PTH levels within a target range of 150-300 pg/mL
• Improve the balance of calcium and phosphate levels in the blood

If successful, PLS240 could provide a new treatment option for managing SHPT in dialysis patients.

Safety and side effects

As PLS240 is still being studied, all of its potential side effects are not yet known. The clinical trials are closely monitoring patients for any adverse effects, including:^[8]

• Changes in blood calcium levels
• Heart rhythm abnormalities
• Other laboratory test changes

Patients in the trials have regular check-ups, blood tests, and ECGs to watch for any safety concerns.

Who may be eligible for PLS240 treatment?

The clinical trials for PLS240 are enrolling patients who meet specific criteria, including:^[9]

• Adults aged 18-80 years
• Diagnosed with end-stage kidney disease and on hemodialysis for at least 3 months
• Have high PTH levels (above 400 pg/mL) despite current treatments
• Do not have certain other medical conditions that could interfere with the study

It’s important to note that PLS240 is still an investigational medication. It is not yet approved for general use outside of clinical trials. Patients interested in learning more should speak with their kidney specialist about current treatment options for SHPT.

Table of Contents

• Trial overview
• Breast cancer studies
• Prostate cancer studies
• Fertility and reproductive studies
• Other studies
• Main endpoints being measured
• Who can participate

Trial overview

The trial data show that Triptorelin is being studied in several different settings, mainly breast cancer, prostate cancer, and fertility treatment.^[1][2] Most studies are Phase 2 or Phase 3 trials, which means they are testing how well the treatment works in larger patient groups and, in some studies, comparing it with other options.^[1][2] Several studies are authorised, some are completed, and one study in the source data is withdrawn.^[1]

Breast cancer studies

Many Triptorelin trials focus on women with ER-positive/HER2-negative or HR-positive/HER2-negative early breast cancer, including both premenopausal and high-risk groups.^[2][3] In these studies, Triptorelin is used with other endocrine treatments, and the trials aim to see whether the treatment plan lowers cancer growth, delays recurrence, or improves invasive breast cancer-free survival.^[2][3]

One Phase 2 study in premenopausal women with operable breast cancer compared giredestrant plus Triptorelin with anastrozole plus Triptorelin, and also looked at giredestrant without Triptorelin.^[2] Its main endpoint was the change in Ki-67, a marker that shows how fast tumor cells are growing, measured between a biopsy before treatment and a biopsy after treatment.^[2]

Large Phase 3 trials also study Triptorelin in early breast cancer, including studies of adjuvant endocrine-based therapy and personalized treatment strategies in young women.^[3][4] These trials measure outcomes such as IBCFS, which is the time until an invasive breast cancer event, a new cancer in the other breast, or death.^[3][4]

Another completed Phase 2 study in metastatic breast cancer compared alpelisib-fulvestrant with ribociclib-fulvestrant in patients with persistent PIK3CA mutations after early treatment with a CDK4/6 inhibitor and fulvestrant.^[5] Triptorelin was one of the hormone treatment options listed in that study, and the main endpoint was progression-free survival.^[5]

Prostate cancer studies

Triptorelin is also studied often in prostate cancer, including localised, locally advanced, recurrent, oligometastatic, and metastatic disease.^[6][7] These studies usually compare different hormone treatment strategies, sometimes together with radiotherapy, and they look at whether the cancer stays controlled for longer or whether the risk of metastasis is reduced.^[6][7]

In a Phase 3 study of very high-risk localised or locally advanced prostate cancer, Triptorelin was one of several GnRH agonists compared with other hormone options alongside radiotherapy.^[6] The main endpoint was the proportion of patients reaching a PSA nadir below 0.1 ng/mL within 6 months after radiotherapy, which means the lowest PSA level achieved after treatment.^[6]

Another Phase 3 study looked at patients with oligorecurrent hormone-sensitive prostate cancer and tested whether adding short-term hormone therapy, including Triptorelin, to metastasis-directed therapy could delay poly-metastatic progression.^[7] That study measured poly-metastatic free survival, which is the time until the disease spreads to more than five new lesions on imaging or until treatment changes because of progression.^[7]

Other prostate cancer trials included Triptorelin in studies of salvage radiotherapy after surgery, darolutamide with or without radiation, and treatment approaches for metastatic castration-sensitive or castration-resistant disease.^[8][9] These studies measure outcomes such as metastasis-free survival, radiographic progression-free survival, biochemical disease-free survival, and quality of life.^[8][9]

Fertility and reproductive studies

Several Triptorelin trials are in fertility care, especially ovarian stimulation, embryo development, and fertility preservation.^[10][11] These studies involve women undergoing IVF, ICSI, oocyte donation, or planned fertility preservation, and they compare different stimulation or triggering approaches.^[10][11]

In ovarian stimulation studies, the main outcomes often focus on the number of MII oocytes, which are mature egg cells, or the number of good-quality blastocysts, which are early embryos with good development.^[10][11] For example, one Phase 3 trial compared intranasal nafarelin with subcutaneous Triptorelin to trigger final oocyte maturation, and another study compared different stimulation intensities in women undergoing PGT-A with a PPOS protocol.^[10][11]

Other fertility trials looked at live birth, clinical pregnancy, or the number of cumulus-oocyte complexes, which are egg cells surrounded by supporting cells collected after stimulation.^[12][13] One study also examined whether a GnRH agonist before frozen embryo transfer improves pregnancy rates in patients with endometriosis and/or adenomyosis.^[12]

There is also a Phase 3 study in women with low ovarian reserve and androgen receptor polymorphism that tested whether pretreatment with transdermal testosterone increases the number of cumulus-oocyte complexes after ovarian stimulation.^[13] This study was withdrawn in the source data, but it still shows the type of fertility questions being studied alongside Triptorelin.^[13]

Other studies

Triptorelin appears in a Phase 2 menopause study that compared a GnRH analog, transdermal estrogen, transdermal testosterone, and placebo over 8 weeks in postmenopausal women.^[14] The main outcome was the change in bone remodeling, measured through bone markers from baseline to week 8.^[14]

Another study looked at the use of Triptorelin in a Phase 1/II metastatic breast cancer trial combining [177Lu]Lu-NeoB with capecitabine, where Triptorelin was one of several hormone-related treatment options listed in the source data.^[15] The Phase I part focused on safety, dose-limiting toxicities, and tolerability, while the Phase II part looked at tumor response, clinical benefit, time to response, duration of response, progression-free survival, and overall survival.^[15]

Main endpoints being measured

The trial data show a wide range of endpoints, depending on the condition being studied.^[1] In cancer trials, common endpoints include survival without recurrence, progression-free survival, metastasis-free survival, PSA response, and changes in tumor markers such as Ki-67.^[2][6][8]

In fertility trials, the main endpoints often include the number of mature eggs, embryo quality, pregnancy rate, and live birth.^[10][11][12] In menopause research, the outcome is linked to bone marker changes, which help show how bone is being broken down or rebuilt.^[14]

Who can participate

Participation depends on the study and the disease being treated.^[1] The source data include premenopausal women with early or metastatic breast cancer, men with prostate cancer at different stages, women undergoing IVF or oocyte donation, postmenopausal women, and patients with endometriosis or adenomyosis.^{[2][6][10][12]}

Many studies have extra entry rules, such as hormone receptor status in breast cancer, the number of metastases in prostate cancer, or ovarian reserve in fertility trials.^[3][7][13] This means the trials are aimed at specific patient groups, not at everyone who uses Triptorelin in routine care.^[1]

Table of Contents

• What is Trametinib?
• How Trametinib Works
• Conditions Treated with Trametinib
• How Trametinib is Administered
• Ongoing Clinical Trials
• Potential Side Effects

What is Trametinib?

Trametinib is a medication used in cancer treatment. It is known by several names, including:

• Mekinist (brand name)
• GSK1120212
• JTP-74057
• MEK Inhibitor GSK1120212

Trametinib belongs to a class of drugs called MEK inhibitors. These drugs work by blocking certain proteins involved in cancer cell growth.^[1]

How Trametinib Works

Trametinib targets and blocks proteins called MEK1 and MEK2. These proteins are part of a pathway in cells that controls growth and survival. In many types of cancer, this pathway is overactive, causing cancer cells to grow and spread uncontrollably. By inhibiting MEK1 and MEK2, trametinib can help stop or slow the growth of cancer cells.^[2]

Specifically, trametinib blocks an enzyme pathway that cancer cells need to grow. When these proteins are blocked, cancer cell growth may be stopped, and the cancer cells may die.^[1]

Conditions Treated with Trametinib

Trametinib is being studied and used to treat various types of cancer, including:

• Advanced or metastatic solid tumors: This refers to cancers that have spread from their original location to other parts of the body.^[3]
• Thyroid cancer: Particularly radioiodine-refractory thyroid cancer, which doesn’t respond to standard radioactive iodine treatment.^[4]
• Cervical cancer: Specifically for recurrent or persistent cervical cancer.^[5]
• Oral cavity squamous cell cancer: A type of mouth cancer.^[2]
• Multiple myeloma: A cancer of plasma cells in the bone marrow.^[6]
• Non-small cell lung cancer (NSCLC): Particularly in patients with certain genetic mutations.^[7]
• Langerhans Cell Histiocytosis (LCH): A rare disorder that can affect various parts of the body.^[8]

How Trametinib is Administered

Trametinib is typically taken orally (by mouth) once daily. The dosage may vary depending on the specific condition being treated and the patient’s individual factors. Some key points about trametinib administration include:

• It is usually given in 28-day cycles.^[6]
• The typical adult dose is 2 mg once daily.^[7]
• For patients who cannot swallow pills, a liquid formulation may be available.^[8]
• Dose adjustments may be necessary based on how well the patient tolerates the medication.^[7]

Ongoing Clinical Trials

Trametinib is being studied in various clinical trials to better understand its effectiveness and safety in different types of cancer. Some ongoing areas of research include:

• Combining trametinib with other medications to enhance its effectiveness.^[4]
• Using trametinib in patients with liver dysfunction.^[1]
• Studying trametinib’s effects on specific genetic mutations in cancer cells.^[7]
• Evaluating trametinib as a treatment for rare disorders like Langerhans Cell Histiocytosis.^[8]

Potential Side Effects

Like all medications, trametinib can cause side effects. Common side effects may include:

• Skin rashes or other skin problems
• Diarrhea
• Fatigue
• Nausea
• Swelling (edema)

More serious side effects can occur, such as heart problems, eye problems, or lung inflammation. Patients should report any unusual symptoms to their healthcare provider promptly.^[1]

It’s important to note that the side effects and their frequency can vary depending on the specific condition being treated and other factors. Your healthcare team will monitor you closely while you’re taking trametinib and can provide more personalized information about potential side effects.

Table of Contents

• What is Tirzepatide?
• How Tirzepatide Works
• Conditions Treated with Tirzepatide
• How Tirzepatide is Administered
• Current Clinical Trials
• Potential Side Effects
• Special Considerations

What is Tirzepatide?

Tirzepatide is a medication that has gained attention in the medical community for its potential in treating various conditions. It’s known by several names, including LY3298176 (its development code name), Mounjaro, and Zepbound (brand names in certain regions)^[1][2]. Tirzepatide is a unique drug that acts as a dual receptor agonist, meaning it activates two different receptors in the body: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor^[3].

How Tirzepatide Works

Tirzepatide is a 39-amino-acid modified peptide with a special structure that allows it to bind to albumin (a protein in the blood) and prolongs its half-life (the time it takes for half of the drug to be eliminated from the body)^[3]. This means that the medication can stay active in your body for a longer time, allowing for less frequent dosing.

The dual action of tirzepatide on both GIP and GLP-1 receptors is believed to contribute to its effectiveness. These receptors play important roles in regulating blood sugar levels, appetite, and metabolism^[4].

Conditions Treated with Tirzepatide

Tirzepatide is being studied for its potential in treating several conditions:

• Type 2 Diabetes: Tirzepatide has shown promise in helping manage blood sugar levels in people with type 2 diabetes^[5].
• Obesity and Weight Management: Clinical trials are exploring the use of tirzepatide for weight loss in people with obesity^[2].
• Hidradenitis Suppurativa: This is a chronic skin condition characterized by painful, inflamed lesions. A study is investigating tirzepatide’s potential in treating moderate to severe cases^[3].
• Wolfram Syndrome: This rare genetic disorder affects multiple body systems. Researchers are studying tirzepatide as a potential treatment^[4].
• Breast Cancer Risk Reduction: A study is looking at how tirzepatide might affect biomarkers related to breast cancer risk in women with obesity^[6].

How Tirzepatide is Administered

Tirzepatide is typically administered as a subcutaneous (under the skin) injection. It’s usually given once a week, and can be injected in the abdomen, thigh, or upper arm^[1]. The dosage may start low and be gradually increased over time to help your body adjust and minimize side effects^[2].

Current Clinical Trials

Several clinical trials are currently underway to further investigate the effects and potential uses of tirzepatide:

• A study on its use in patients with hormone receptor-positive, HER2-negative breast cancer^[2].
• Research on its effectiveness in people with type 2 diabetes during Ramadan fasting^[5].
• Investigation of its potential in treating Wolfram Syndrome^[4].
• A study on how it affects various biomarkers in women with obesity who are at risk for breast cancer^[6].

Potential Side Effects

As with any medication, tirzepatide may cause side effects. Common side effects reported in clinical trials include:

• Gastrointestinal issues such as nausea, vomiting, or diarrhea^[5].
• Hypoglycemia (low blood sugar), especially in patients with diabetes^[5].

It’s important to discuss potential side effects with your healthcare provider before starting tirzepatide.

Special Considerations

Some special considerations for tirzepatide include:

• Pregnancy and Breastfeeding: A study is being conducted to evaluate tirzepatide concentrations in breast milk, which will provide important information for breastfeeding mothers^[7].
• Body Size: Research is being done to understand how body size might affect the way tirzepatide is absorbed and processed by the body^[1].
• Fasting: A study is looking at how tirzepatide can be used safely and effectively by people with type 2 diabetes who fast during Ramadan^[5].

As tirzepatide is still being studied for many conditions, it’s crucial to consult with your healthcare provider about whether it might be appropriate for you and to stay informed about the latest research findings.

Table of Contents

• What is Tiratricol?
• What Conditions Does Tiratricol Treat?
• How Does Tiratricol Work?
• How is Tiratricol Administered?
• Current Clinical Trials
• Potential Benefits of Tiratricol
• Possible Side Effects and Monitoring

What is Tiratricol?

Tiratricol, also known by its other names Triac, Téatrois, or TA3, is a thyroid hormone analog. This means it’s a medication that mimics the action of thyroid hormones in the body. Tiratricol is a naturally occurring metabolite (breakdown product) of T3, which is one of the main thyroid hormones^[1]. It has similar biological activity and binds to the same receptors in the body as T3, making it a promising treatment for certain thyroid-related disorders.

What Conditions Does Tiratricol Treat?

Tiratricol is being studied primarily for the treatment of a rare genetic condition called Monocarboxylate Transporter 8 (MCT8) Deficiency. This condition is also known as Allan-Herndon-Dudley Syndrome (AHDS)^[2]. MCT8 deficiency is caused by mutations in the MCT8 gene, which is responsible for transporting thyroid hormones into cells, especially in the brain^[1].

People with MCT8 deficiency experience a range of symptoms, including:

• Severe intellectual and motor disabilities: This is due to a lack of thyroid hormones in the brain, leading to impaired brain development.
• Low body weight and reduced muscle mass: This is caused by high levels of thyroid hormones in other parts of the body.
• Abnormal thyroid hormone levels in the blood: Typically, these patients have high T3, low T4, and normal TSH levels^[1].

How Does Tiratricol Work?

Tiratricol works in a unique way that makes it particularly suitable for treating MCT8 deficiency:

1. Independent transport: Unlike regular thyroid hormones, Tiratricol doesn’t rely on the MCT8 transporter to enter cells. This means it can reach tissues that are normally deprived of thyroid hormones in MCT8 deficiency, including the brain^[3].
2. Similar action to T3: Once inside the cells, Tiratricol binds to the same receptors as T3, potentially restoring normal thyroid hormone function^[1].
3. Normalization of thyroid levels: Tiratricol treatment aims to reduce the high T3 levels in the blood, which can help alleviate some of the symptoms caused by thyroid hormone excess in certain tissues^[3].

How is Tiratricol Administered?

Tiratricol is available as tablets containing 350 micrograms of the medication. It can be administered in several ways:

• Oral administration: The tablets are suspended in water and can be mixed with food if needed.
• Tube feeding: For patients who cannot take medication by mouth, Tiratricol can be given through a percutaneous endoscopic gastrostomy (PEG) tube, nasogastric tube, or jejunal tube^[2].

The dosage is individually tailored for each patient, starting with a low dose and gradually increasing to reach the optimal level^[1].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness and safety of Tiratricol in treating MCT8 deficiency:

• Expanded Access Program: This program aims to provide Tiratricol to patients with MCT8 deficiency before it receives marketing authorization^[2].
• Triac Trial II: This study is investigating the effects of Tiratricol on young boys (30 months or younger) with MCT8 deficiency^[3].
• Withdrawal Study: This trial is examining what happens when Tiratricol treatment is stopped in patients who have been receiving it^[4].

Potential Benefits of Tiratricol

Based on current research, Tiratricol may offer several benefits for patients with MCT8 deficiency:

• Improved brain development: By providing thyroid hormone-like activity to the brain, Tiratricol may help improve cognitive and motor function^[3].
• Normalized thyroid hormone levels: Tiratricol treatment aims to reduce the high T3 levels in the blood, which can help alleviate symptoms of thyroid hormone excess in certain tissues^[1].
• Better growth and muscle development: By addressing the thyroid hormone imbalance, Tiratricol may help improve body weight and muscle mass^[1].
• Improved heart function: Tiratricol may help normalize heart rate and other cardiovascular parameters affected by thyroid hormone imbalance^[4].

Possible Side Effects and Monitoring

While Tiratricol shows promise, it’s important to monitor patients closely for potential side effects. During clinical trials, researchers are keeping track of:

• Thyroid hormone levels: Regular blood tests are conducted to ensure thyroid hormone levels remain within the target range^[4].
• Heart function: ECGs and heart rate monitoring are performed to check for any cardiac effects^[1].
• Liver function: Blood tests are done to monitor liver enzymes and other markers of liver health^[4].
• Bone density: Some studies are measuring bone mineral density to ensure Tiratricol doesn’t negatively affect bone health^[1].
• General health: Patients are monitored for any adverse events or unexpected side effects throughout the treatment period^[2].

It’s important to note that as Tiratricol is still being studied, all potential side effects may not be known yet. Patients receiving this treatment should be in close contact with their healthcare providers and report any unusual symptoms promptly.

Table of Contents

• What is Tiemonium Methylsulphate?
• Medical Conditions Treated
• Combination with Other Medications
• Administration and Dosage
• Potential Benefits
• Important Considerations

What is Tiemonium Methylsulphate?

Tiemonium Methylsulphate is a medication that belongs to a class of drugs known as anticholinergics. It is also referred to as Tiemonium metilsulfate in some contexts^[1]. This medication is often used in combination with other drugs to treat various medical conditions, particularly those affecting the musculoskeletal system.

Medical Conditions Treated

While the primary focus of the clinical trial data is on a condition called calcium pyrophosphate deposition disease (CPPD), Tiemonium Methylsulphate is being studied in combination with other medications for its potential benefits in treating this condition^[1]. CPPD is a form of arthritis caused by the buildup of calcium pyrophosphate crystals in the joints, leading to inflammation and pain.

Combination with Other Medications

In the clinical trial, Tiemonium Methylsulphate is being studied in combination with Colchicine. This combination is being compared to other treatment options for CPPD, including:

• Methylprednisolone: A corticosteroid used to reduce inflammation
• Colchicine: A medication commonly used to treat gout and other inflammatory conditions
• Hydroxychloroquine: An antimalarial drug also used to treat certain autoimmune diseases
• Methotrexate (MTX): A medication used to treat various inflammatory conditions and certain types of cancer

The combination of these medications is being studied to determine the most effective treatment approach for patients with CPPD^[1].

Administration and Dosage

The specific dosage of Tiemonium Methylsulphate is not provided in the clinical trial data. However, the combination medication (Colchicine with Tiemonium Methylsulphate) is administered as follows:

• 1 mg tablets
• Taken once daily after breakfast
• The dosage may be adjusted to 1 or ½ tablet, depending on individual tolerance

It’s important to note that this dosage information is specific to the clinical trial and may not reflect the typical dosage for all patients^[1].

Potential Benefits

While the specific benefits of Tiemonium Methylsulphate are not directly stated in the clinical trial data, the combination therapy is being studied for its potential to:

• Reduce inflammation in the joints affected by CPPD
• Improve patient-reported outcomes and pain levels
• Decrease calcium crystal deposition in the joints
• Reduce synovitis (inflammation of the synovial membrane in the joints)

These potential benefits are being evaluated through various measures, including changes in pain scores, functional assessments, and imaging studies^[1].

Important Considerations

When considering treatment with Tiemonium Methylsulphate or any medication, it’s essential to keep the following points in mind:

• Always follow your doctor’s instructions regarding dosage and administration.
• Inform your healthcare provider about any other medications you’re taking, as drug interactions may occur.
• Be aware of potential side effects and report any unusual symptoms to your doctor.
• Regular follow-ups and monitoring may be necessary to assess the medication’s effectiveness and safety.

As with any medication, the use of Tiemonium Methylsulphate should be carefully considered by your healthcare provider based on your individual medical history and current condition^[1].

Table of Contents

• What is Thiamazole?
• Conditions Treated by Thiamazole
• How Thiamazole Works
• Dosage and Administration
• Clinical Studies and Research
• Potential Side Effects
• Important Considerations

What is Thiamazole?

Thiamazole, also known as methimazole, is a medication primarily used to treat hyperthyroidism, a condition where the thyroid gland produces too much thyroid hormone^[1]. It belongs to a class of drugs called antithyroid medications. Thiamazole is marketed under various brand names, including Tapazole, Thyrozol, and Northyx^[2].

Conditions Treated by Thiamazole

Thiamazole is primarily used to treat the following conditions:

• Graves’ Disease: This is the most common cause of hyperthyroidism, where the immune system mistakenly attacks the thyroid gland, causing it to produce excess thyroid hormones^[1].
• Hyperthyroidism: A general condition of overactive thyroid, which can have various causes^[3].
• Preparation for Thyroid Surgery: Thiamazole may be used to control hyperthyroidism before thyroid surgery^[1].

Interestingly, recent research is also exploring the potential use of thiamazole in treating certain types of brain tumors, specifically glioblastoma^[2]. However, this is still in the experimental stage and not an approved use of the medication.

How Thiamazole Works

Thiamazole works by blocking the production of thyroid hormones in the thyroid gland. Specifically, it inhibits an enzyme called thyroid peroxidase, which is crucial for adding iodine to thyroid hormones^[4]. By reducing the amount of thyroid hormones produced, thiamazole helps to control the symptoms of hyperthyroidism and bring thyroid function back to normal levels.

Dosage and Administration

The dosage of thiamazole can vary depending on the severity of hyperthyroidism and individual patient factors. Here are some general guidelines based on clinical studies:

• Initial doses may range from 15 to 30 mg per day, divided into multiple doses^[1].
• The dose is typically adjusted based on thyroid function tests, which are usually performed every 4-8 weeks^[5].
• As thyroid function improves, the dose may be gradually reduced to a maintenance dose of 2.5-5.0 mg per day^[5].

It’s crucial to take thiamazole exactly as prescribed by your doctor and to attend all follow-up appointments for monitoring thyroid function.

Clinical Studies and Research

Several clinical studies have been conducted to evaluate the effectiveness of thiamazole in treating hyperthyroidism and explore its potential in other areas:

• A study examined the optimal time to discontinue thiamazole before radioactive iodine therapy in Graves’ disease patients^[1].
• Another study investigated the effects of thiamazole on islet β-cell functions in Chinese patients with Graves’ disease^[6].
• Researchers are exploring the potential use of thiamazole in treating glioblastoma, a type of brain tumor^[2].

Potential Side Effects

While thiamazole is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

• Skin rashes or itching
• Nausea or stomach upset
• Headaches
• Joint pain

In rare cases, more serious side effects can occur, such as liver problems or a decrease in white blood cell count. It’s important to report any unusual symptoms to your doctor promptly^[5].

Important Considerations

When taking thiamazole, keep the following in mind:

• Regular blood tests are necessary to monitor thyroid function and adjust the dosage as needed^[5].
• Thiamazole may take several weeks to fully control hyperthyroidism symptoms.
• Do not stop taking thiamazole without consulting your doctor, as this can lead to a recurrence of hyperthyroidism^[5].
• Inform your doctor if you are pregnant or planning to become pregnant, as special considerations may apply.

Remember, thiamazole is a powerful medication that requires careful monitoring and management by a healthcare professional. Always follow your doctor’s instructions and report any concerns or side effects promptly.

Table of Contents

• What is Testosterone?
• Medical Uses of Testosterone
• Forms and Administration of Testosterone
• Effectiveness of Testosterone Therapy
• Potential Side Effects and Monitoring
• Ongoing Research and Future Directions

What is Testosterone?

Testosterone is a hormone that plays a crucial role in male health. It is primarily produced by the testes in men and is responsible for many masculine characteristics, such as muscle mass, body hair, and deep voice. In medical terms, testosterone is often referred to as an androgen, which means a male hormone^[1].

Medical Uses of Testosterone

Testosterone is primarily used to treat a condition called hypogonadism, which is when the body doesn’t produce enough testosterone on its own. This condition can cause various symptoms, including^[2][3]:

• Low energy levels
• Reduced muscle mass
• Decreased sexual function
• Changes in mood or cognitive function

In addition to hypogonadism, testosterone therapy is also being studied for its potential benefits in certain cases of prostate cancer. While this might seem counterintuitive, some research suggests that in specific situations, testosterone might help manage hormone-refractory prostate cancer, which is a type of prostate cancer that no longer responds to standard hormone therapy^[1].

Forms and Administration of Testosterone

Testosterone replacement therapy comes in several forms, each with its own advantages. Some of the common forms include^[4][1][5]:

• Testosterone pellets (Testopel®): These are small pellets implanted under the skin, usually in the hip area. They slowly release testosterone over several months.
• Transdermal patches (Androderm®): These are patches applied to the skin daily, delivering a steady dose of testosterone.
• Oral capsules: Some forms of testosterone can be taken by mouth, such as testosterone undecanoate (LPCN 1021).

The choice of form depends on various factors, including patient preference, lifestyle, and specific medical needs.

Effectiveness of Testosterone Therapy

The effectiveness of testosterone therapy is typically measured by monitoring testosterone levels in the blood and assessing symptom improvement. Studies have shown that testosterone replacement can effectively raise testosterone levels to the normal range in most patients with hypogonadism^[2][3].

For example, one study found that after 24 days of treatment with oral testosterone undecanoate, a significant proportion of patients achieved normal testosterone levels^[2]. Another study using testosterone pellets showed that testosterone levels could be maintained in the therapeutic range for 4-6 months after a single implantation^[4].

Potential Side Effects and Monitoring

While testosterone therapy can be beneficial, it’s important to be aware of potential side effects. Regular monitoring is crucial to ensure safe and effective treatment. Some key aspects that are typically monitored include^[4][5]:

• Testosterone levels: To ensure they remain within the normal range.
• Hematocrit levels: Testosterone can increase red blood cell production, which might lead to blood thickening in some cases.
• PSA (Prostate Specific Antigen) levels: To monitor prostate health, as testosterone might affect the prostate gland.
• Estradiol levels: Some testosterone can be converted to estrogen in the body, so estradiol (a form of estrogen) is also monitored.
• Blood pressure: Some studies are investigating the effects of testosterone on blood pressure.

Ongoing Research and Future Directions

Research on testosterone therapy is ongoing, with scientists exploring its potential benefits and risks in various conditions. Some areas of current research include^[6][5]:

• The use of new imaging techniques, such as PET scans with special tracers, to better understand how testosterone interacts with prostate cancer cells.
• The effects of testosterone therapy on cardiovascular health, including blood pressure.
• The potential benefits of testosterone on quality of life, sexual function, and muscle strength in men with low testosterone levels.

These ongoing studies aim to provide a more comprehensive understanding of testosterone’s role in health and disease, potentially leading to improved treatments in the future.

Table of Contents

• What is Testosterone Undecanoate?
• Medical Conditions Treated
• Administration and Dosage
• Benefits and Effects
• Potential Side Effects
• Ongoing Research

What is Testosterone Undecanoate?

Testosterone Undecanoate is a form of testosterone replacement therapy used to treat various conditions related to low testosterone levels in men. It’s also known by brand names such as Nebido, Aveed, and Andriol^[1][2]. This medication is designed to mimic the body’s natural testosterone production, helping to alleviate symptoms associated with low testosterone levels.

Medical Conditions Treated

Testosterone Undecanoate is primarily used to treat the following conditions:

• Male Hypogonadism: This is a condition where the body doesn’t produce enough testosterone. It can be caused by problems with the testicles or the pituitary gland^[1].
• Delayed Puberty: In some cases, it may be used to help start puberty in boys who are late in developing^[3].
• Muscle Loss: It can help prevent muscle loss in certain situations, such as after bariatric surgery^[4].

Administration and Dosage

Testosterone Undecanoate is typically administered in one of two ways:

1. Intramuscular Injection: This is the most common form. It’s usually given as a deep injection into the buttock muscle. The typical dose is 1000 mg, given at intervals of 10-14 weeks^[1].
2. Oral Capsules: In some cases, it may be given as oral capsules. However, this form is less common and may require more frequent dosing^[2].

The exact dosage and frequency will be determined by your doctor based on your individual needs and response to the treatment.

Benefits and Effects

Testosterone Undecanoate can have several positive effects on the body:

• Improved Sexual Function: It can help improve libido (sex drive) and erectile function^[1].
• Increased Muscle Mass and Strength: It can help build and maintain muscle mass, which is particularly beneficial for men experiencing muscle loss^[4].
• Improved Bone Density: Testosterone plays a role in maintaining bone strength, and replacement therapy can help prevent bone loss^[4].
• Better Mood and Quality of Life: Some men report improved mood and overall quality of life when their testosterone levels are normalized^[1].

Potential Side Effects

While Testosterone Undecanoate can be beneficial, it’s important to be aware of potential side effects:

• Increased Red Blood Cell Count: This can potentially increase the risk of blood clots^[4].
• Prostate Changes: There may be an increased risk of prostate enlargement or prostate cancer, which is why regular prostate exams are important during treatment^[4].
• Acne and Oily Skin: Some men may experience increased acne or oilier skin^[5].
• Sleep Apnea: In some cases, testosterone therapy may worsen existing sleep apnea^[4].

It’s crucial to discuss all potential risks and benefits with your healthcare provider before starting treatment.

Ongoing Research

Researchers are continually studying Testosterone Undecanoate to better understand its effects and potential uses. Some areas of ongoing research include:

• Use in Bariatric Surgery Patients: Studies are investigating whether testosterone therapy can help prevent muscle loss in men undergoing weight loss surgery^[4].
• Effects on Physical Performance: Research is being conducted on how testosterone therapy might improve physical performance during intense activities, such as military operations^[6].
• Treatment of Non-alcoholic Steatohepatitis (NASH): Some studies are exploring whether testosterone therapy could help improve liver health in men with NASH, a type of fatty liver disease^[7].

These ongoing studies may lead to new uses for Testosterone Undecanoate in the future, potentially benefiting more patients with various health conditions.

Table of contents

• Clinical trials overview
• Who the trials are for
• What the studies are testing
• Main outcomes measured
• Trial-by-trial summary
• Key points for patients

Clinical trials overview

The available studies are interventional trials, which means researchers give a treatment and then measure the results.^[1] All listed trials are investigating Somapacitan in children with growth-related conditions, and the studies are either Phase 2 or Phase 3.^[1][2][3][4]

Three of the studies are authorised, and one is completed.^[1][2][3][4] The largest study listed has 412 participants, while the smallest has 44 participants.^[1][2]

Who the trials are for

The trials focus on children who need help to grow.^[1][2][3][4] The child groups include growth hormone deficiency, small for gestational age (born smaller than expected for pregnancy age), Turner syndrome, Noonan syndrome, and idiopathic short stature (short height with no clear cause).^[1][2][3][4]

Some studies include several conditions in one trial, while another study focuses only on children with SGA who did not show catch-up growth by 2 years of age or older.^[1][3] One study also includes children who were either new to growth hormone treatment or had already received it before.^[2]

What the studies are testing

Most trials compare once-weekly Somapacitan with once-daily Norditropin®, which is the standard treatment used in these studies.^[1][3][4] The goal is to see whether the weekly treatment works as well as the daily treatment for growth.^[1][3][4]

One Phase 3 study, REAL 9, looks mainly at safety in children with the four listed growth conditions.^[2] Safety is measured by counting adverse events, which are unwanted health problems that happen during the study.^[2]

The Phase 2 study in children born SGA also compares Somapacitan with Norditropin® and checks whether the weekly treatment improves growth over 26 weeks.^[3] The Phase 3 studies in children with short stature or growth hormone deficiency use a similar comparison but follow children longer, up to 52 weeks in two of the studies.^[1][4]

Main outcomes measured

The main outcome in most trials is height velocity, which means how fast a child grows in height over time.^[1][3][4] This outcome is usually measured in cm per year and helps show whether the treatment supports normal growth.^[3][4]

In the REAL 9 study, the main outcome is the number of adverse events from week 0 to week 26.^[2] In the other studies, the main focus is growth over time, with one study measuring from baseline to week 26 and two studies measuring from baseline to week 52.^[1][3][4]

Trial-by-trial summary

Here is a simple view of each study and what it is trying to answer.^[1][2][3][4]

• 2023-506927-27-00: A Phase 3 study in 412 children with SGA, Turner syndrome, Noonan syndrome, or idiopathic short stature. It compares once-weekly Somapacitan with once-daily Norditropin® and checks height velocity at week 52.^[1]

• 2022-501055-87-01: A Phase 3 safety study in 44 children with the same four conditions. It looks at adverse events over 26 weeks and includes children who are new to growth hormone treatment or not new to it.^[2]

• 2023-506830-66-00: A Phase 2 study in 62 children born SGA who did not show catch-up growth. It compares Somapacitan with Norditropin® and measures height velocity from week 0 to week 26.^[3]

• 2023-506829-11-00: A completed Phase 3 study in 200 children with growth hormone deficiency. It compares Somapacitan with Norditropin® and measures height velocity from week 0 to week 52.^[4]

Key points for patients

These trials are not testing Somapacitan in adults or in many other diseases; they are focused on children with growth problems.^[1][2][3][4] The main question is whether a once-weekly treatment can help children grow as well as the daily treatment used as a comparison.^[1][3][4]

Because the studies measure growth over time, they help researchers understand both the benefit and the safety of treatment in real patient groups.^[2] The results are based on the listed study phases, participant numbers, and outcomes shown in the trial data.^[1][2][3][4]

Table of Contents

• Trial overview
• Who is being studied
• Trial designs and phases
• What the trials measure
• Key treatment comparisons
• What these studies may mean for patients

Trial overview

The trial data show several studies that investigate Somatropin-related growth treatment in children and, in one study, hormone and metabolism questions in adults.^{[1][2][3][4][5][6][7]} Most of the studies are interventional trials, which means researchers give a treatment and then measure the results.^{[1][2][3][4][5][6][7]}

Who is being studied

Several trials focus on children with growth hormone deficiency, which means the body does not make enough growth hormone for normal growth.^[1][5] Other studies include children who were small for gestational age (SGA), children with Turner syndrome, Noonan syndrome, idiopathic short stature, or SHOX-D.^[2][3][7] One trial is in boys with short predicted height, meaning the study expects their adult height may be lower than average.^[4]

One Phase 2 study includes people with acromegaly and healthy volunteers, and it looks at metabolism in humans.^[6] This makes the trial set broader than growth studies alone, but the main focus across the data is still growth-related research.^{[1][2][3][4][5][7]}

Trial designs and phases

The listed studies are mainly in Phase 3, with two studies in Phase 2.^{[1][2][3][4][5][6][7]} Phase 2 studies usually look at early effects in a smaller group, while Phase 3 studies test treatment effects in larger groups and often compare different options.^[3][6] Enrollment ranges from 30 people to 412 people, showing that some studies are small and focused while others are larger comparison trials.^[2][6]

Several studies compare weekly treatment with daily treatment, especially weekly somapacitan-based regimens versus daily Norditropin®.^[1][2][3] One Phase 3 study compares daily Somatropin with weekly lonapegsomatropin in children and adolescents.^[7]

What the trials measure

The most common primary outcome is height velocity, which means how fast a child grows over time, usually measured in centimeters per year.^[1][2][3][7] One study measures height velocity from baseline to week 52, while another measures it from baseline to week 26.^[1][3] The Phase 3 GHD Reversal Trial measures Final Height in Standard Deviation Score (FH SDS), which compares final height with the average height expected for age and sex.^[5]

The OMNIMARA Trial measures adult height gain, defined as final height minus predicted adult height.^[4] The metabolism study measures GH-induced changes in energy-rich phosphate metabolism, including ATP turnover, which is a way to look at how the body uses energy.^[6] These outcomes show that the trials are not only checking whether treatment helps children grow, but also whether it changes longer-term height and body metabolism.^[1][4][6]

Key treatment comparisons

Several trials compare Somatropin-related weekly treatment with daily Norditropin®.^[1][2][3] In the growth hormone deficiency study, children receive somapacitan once a week or Norditropin® once a day.^[1] In the SGA study, children born small and who stayed small are also treated with weekly somapacitan or daily Norditropin®.^[3]

The study in children with short stature linked to SGA, Turner syndrome, Noonan syndrome, or idiopathic short stature aims to confirm that weekly somapacitan is non-inferior, meaning it is not worse than daily Norditropin® by more than a set amount.^[2] The Phase 3 trial in children with short predicted height tests whether combining GH treatment with letrozole during puberty gives more adult height gain than GH alone.^[4] Another Phase 3 study compares weekly lonapegsomatropin with daily Somatropin in children and adolescents with growth failure due to growth hormone sufficient disorders.^[7]

What these studies may mean for patients

For patients and families, these trials mainly ask whether different growth treatments can help children grow better, with fewer injections or different treatment schedules.^[1][2][3][7] The studies also try to understand whether treatment can improve final adult height, not only short-term growth.^[4][5] Because the trials include different growth conditions, they help researchers learn which children may benefit most from each treatment approach.^{[1][2][3][4][5][7]}

Table of contents

• Trials at a glance
• Type 1 diabetes and cardiovascular risk
• Post-bariatric hypoglycaemia
• Kidney complications in type 1 diabetes
• Hypertrophic cardiomyopathy
• Study designs and endpoints
• Who the studies are for

Trials at a glance

Clinical trials of Sotagliflozin in the source data are being done in four main patient groups: people with type 1 diabetes, people with post-bariatric hypoglycaemia, people with chronic kidney complications linked to type 1 diabetes, and people with hypertrophic cardiomyopathy.^[1][2][3][4]

The trials are authorised and include both Phase 2 and Phase 3 studies.^[1][2][3][4]

The studies are interventional, which means participants receive a study treatment and outcomes are measured over time.^[1][2][3][4]

Type 1 diabetes and cardiovascular risk

One Phase 3 trial is studying a strategy of intensified care in people with type 1 diabetes who are at high risk of cardiovascular disease.^[1]

This study is large, with an enrollment of 2050 people, and it compares a multifactorial intervention strategy with standard care.^[1]

The main outcome is time to the first major adverse cardiovascular event (MACE), which includes non-fatal heart attack, non-fatal stroke, cardiovascular death, or first hospitalization for heart failure.^[1]

The trial also includes safety and efficacy evaluation of 40 mg finerenone in people with type 1 diabetes who are at risk of cardiovascular death and hospitalization for heart failure, but Sotagliflozin is listed among the study interventions in this trial record.^[1]

Post-bariatric hypoglycaemia

The ONSIDE study is a Phase 2 trial of Sotagliflozin for post-bariatric hypoglycaemia, which means low blood sugar that happens after bariatric surgery.^[2]

This study includes 24 participants and uses a randomized, double-blind, placebo-controlled crossover design.^[2]

Participants are people who had Roux-en-Y gastric bypass surgery and have confirmed biochemical post-bariatric hypoglycaemia.^[2]

The main outcome is time spent in level 2 hypoglycaemia, defined in the source as glucose below 3.0 mmol/L, measured by continuous glucose monitoring during the outpatient part of the study.^[2]

Participants receive Sotagliflozin 400 mg once daily and placebo in random order for four weeks each.^[2]

Kidney complications in type 1 diabetes

The PLUTO study is a Phase 2 trial in people with Type 1 Diabetes Mellitus with chronic kidney complications.^[3]

It has an enrollment of 69 participants and compares Sotagliflozin with a matching placebo product.^[3]

The main outcome is the change from baseline to 12 weeks in a dynamic R2*-weighted signal on BOLD MRI, which is used as an indirect measure of renal blood oxygenation.^[3]

The brief summary says the study aims to estimate the effect of three months of Sotagliflozin on renal oxygenation in people with type 1 diabetes and chronic kidney disease.^[3]

Hypertrophic cardiomyopathy

Another Phase 3 trial is studying whether Sotagliflozin improves symptoms and is safe in people with hypertrophic cardiomyopathy.^[4]

The listed condition names include obstructive cardiomyopathy, hypertrophic, and non-obstructive hypertrophic cardiomyopathy.^[4]

This study plans to enroll 500 participants and compares Sotagliflozin with placebo.^[4]

The primary outcome is the change from baseline to week 26 in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, which measures symptoms and functional limitations.^[4]

Study designs and endpoints

Across the trial records, the main study designs include placebo comparison, crossover treatment, and large Phase 3 testing against standard care or placebo.^[1][2][3][4]

Endpoints, which are the main results the study wants to measure, are different in each trial and match the condition being studied.^[1][2][3][4]

• Cardiovascular outcomes: the type 1 diabetes study measures serious heart and blood vessel events, including heart attack, stroke, cardiovascular death, and heart failure hospitalization.^[1]
• Low blood sugar time: the post-bariatric hypoglycaemia study measures how much time people spend with very low glucose levels.^[2]
• Kidney oxygenation: the kidney study uses MRI-based signals to estimate how well the kidney is oxygenated.^[3]
• Symptom score: the cardiomyopathy study uses a questionnaire score to track symptoms and daily function.^[4]

Who the studies are for

These trials are not for the general public; each one is aimed at a specific patient group described in the source data.^[1][2][3][4]

People in the studies may have type 1 diabetes with high cardiovascular risk, confirmed post-bariatric hypoglycaemia after Roux-en-Y gastric bypass, chronic kidney disease linked to type 1 diabetes, or symptomatic hypertrophic cardiomyopathy.^[1][2][3][4]

In simple terms, the research is trying to learn where Sotagliflozin may help most, and what outcomes should be measured in each disease area.^[1][2][3][4]

Table of contents

• Clinical trials overview
• Turner syndrome study
• Hemodialysis study
• Outcomes and measures
• What patients should know

Clinical trials overview

The provided data include two interventional studies, which means researchers give a treatment and then measure the results.^[1][2]

Both studies are authorised, and both include SODIUM HYDROXIDE as part of the study intervention.^[1][2]

One study is in Phase 2 and the other is in Phase 3, so the research is already testing effects in people rather than only in early lab work.^[1][2]

Turner syndrome study

The first trial is titled Testosterone Replacement Therapy in Women with Turner Syndrome and includes women with Turner syndrome.^[1]

This is a Phase 2 study with an enrollment of 50 participants.^[1]

The brief summary says the study aims to evaluate the endocrine, physiological, cardiovascular, neurocognitive, and genomic effects of transdermal TRT as a supplement to ERT in women with TS.^[1]

In simple words, the study is checking how this treatment may affect hormones, body function, heart and blood vessel health, thinking skills, and genes in this patient group.^[1]

The intervention list includes SODIUM HYDROXIDE together with other ingredients in a transdermal product, which means it is applied through the skin.^[1]

Hemodialysis study

The second trial is titled LOTUS and includes patients with muscle protein turnover issues who are on hemodialysis.^[2]

This is a Phase 3 study with an enrollment of 20 participants.^[2]

The brief summary says the study is designed to look at the effect of IDPN on muscle protein synthesis in chronic hemodialysis patients and to characterize the hemodynamic effects of IDPN.^[2]

The primary outcome is the difference in myofibrillar fractional synthetic rate during one week of treatment with IDPN versus control.^[2]

This means the researchers want to see whether treatment changes the speed at which muscle protein is made, compared with a control group.^[2]

In this trial data, SODIUM HYDROXIDE appears within a combination intervention used in the study setting.^[2]

Outcomes and measures

In the Turner syndrome study, the main outcome is body composition, measured by total body DXA-scan.^[1]

The DXA scan looks at bone mass, visceral fat, subcutaneous fat, lean muscle mass, abdominal circumference, and weight.^[1]

In the hemodialysis study, the main outcome is the myofibrillar fractional synthetic rate, which is a measure of muscle protein building.^[2]

The study also looks at hemodynamic effects, meaning effects on circulation and blood flow.^[2]

What patients should know

These trials are focused on specific groups, so not everyone would be eligible.^[1][2]

One study is for women with Turner syndrome, while the other is for chronic hemodialysis patients with muscle protein turnover concerns.^[1][2]

The data do not describe SODIUM HYDROXIDE as a stand-alone treatment goal; instead, it appears as part of a larger study product or combination.^[1][2]

Because the trials measure specific outcomes, they are designed to answer research questions about how the interventions affect the body in these patient groups.^[1][2]

Table of Contents

• What is Sodium Iodide (131I)?
• Medical Conditions Treated
• How It Works
• Administration and Dosage
• Effectiveness
• Side Effects and Precautions
• Ongoing Research

What is Sodium Iodide (131I)?

Sodium Iodide (131I), also known as radioactive iodine or RAI, is a radioactive form of iodine used in medical treatments^[1]. It is primarily used to treat certain thyroid conditions and thyroid cancer. This medication is available in different forms, including capsules and solutions, and is administered orally^[2].

Medical Conditions Treated

Sodium Iodide (131I) is used to treat several thyroid-related conditions:

• Differentiated Thyroid Cancer (DTC): This includes papillary and follicular thyroid cancers^[1].
• Graves’ Disease: An autoimmune disorder causing hyperthyroidism (overactive thyroid)^[3].
• Graves’ Orbitopathy (GO): An eye condition associated with Graves’ disease^[3].
• Metastatic Thyroid Cancer: Cancer that has spread beyond the thyroid gland^[2].

How It Works

Sodium Iodide (131I) works by targeting thyroid cells, including cancerous ones. The thyroid gland naturally absorbs iodine, and when radioactive iodine is introduced, it is taken up by thyroid cells. The radiation then destroys these cells, effectively treating thyroid cancer or reducing an overactive thyroid^[1][2].

Administration and Dosage

Sodium Iodide (131I) is typically administered orally in the form of capsules or solution. The dosage varies depending on the condition being treated and individual patient factors. For thyroid cancer treatment, doses can range from 3.7 GBq (gigabecquerels) to 7.4 GBq^[1]. In some cases, personalized dosing based on pre-treatment imaging may be used to optimize treatment^[2].

Effectiveness

The effectiveness of Sodium Iodide (131I) treatment can vary depending on the condition:

• For thyroid cancer, it has been shown to be effective in destroying remaining thyroid tissue after surgery and treating metastatic disease^[1].
• In Graves’ disease, it can effectively reduce thyroid function to manage hyperthyroidism^[3].

Ongoing research is exploring ways to optimize treatment effectiveness, such as using pre-treatment imaging to guide dosing^[2].

Side Effects and Precautions

While Sodium Iodide (131I) is generally well-tolerated, it can cause side effects and requires certain precautions:

• Short-term side effects may include nausea, dry mouth, and changes in taste^[1].
• Long-term effects can include an increased risk of developing other cancers, though this risk is generally low^[1].
• Precautions: Patients should avoid close contact with others, especially pregnant women and young children, for a period after treatment due to radiation exposure^[1].
• Women who are pregnant or breastfeeding should not receive this treatment^[3].

Ongoing Research

Several clinical trials are currently exploring ways to improve the use of Sodium Iodide (131I) in treating thyroid conditions:

• A study is comparing systematic radioiodine administration versus a guided approach based on post-operative evaluation in intermediate-risk thyroid cancer patients^[1].
• Another trial is investigating personalized therapy for metastatic thyroid cancer using pre-treatment imaging to optimize dosing^[2].
• Research is also being conducted to compare the effects of radioiodine treatment versus antithyroid drugs in patients with Graves’ disease and active Graves’ orbitopathy^[3].

These studies aim to improve treatment outcomes, minimize side effects, and personalize therapy for individual patients.

Table of Contents

• Overview of Sodium Chloride in trials
• What these trials are testing
• Who is included
• Trial phases and study size
• Main outcomes being measured
• Selected important trials
• What this means for patients

Overview of Sodium Chloride in trials

Sodium Chloride appears in many studies as a placebo, a control, or a comparison fluid.^[1] In these trials, the main question is usually about another treatment, procedure, or care strategy, not Sodium Chloride itself.^[1]

The trial topics are very broad and include surgery, infection, pain, kidney disease, heart disease, lung disease, brain injury, and allergy testing.^[1] Some studies also use Sodium Chloride as part of the study process in early safety research or in procedure-based trials.^[1]

What these trials are testing

Many trials compare an active treatment against Sodium Chloride to see if the active treatment improves a health outcome.^[1] Examples include pain control after surgery, infection prevention, recovery after critical illness, and changes in organ function.^[1]

• Pain and recovery studies look at things like opioid use, pain scores, mobility, and quality of recovery after surgery.^[1]

• Infection and inflammation studies look at outcomes such as mortality, infection rates, inflammatory markers, and time to clinical recovery.^[1]

• Organ function studies look at kidney, lung, heart, or brain outcomes, such as creatinine, forced vital capacity, ejection fraction, or neurological recovery.^[1]

• Procedure studies compare a treatment or technique with a placebo or sham procedure to see if it improves comfort, safety, or success of the procedure.^[1]

Who is included

The target populations are very different from one trial to another.^[1] Some studies include adults with chronic diseases such as cirrhosis, cancer, autoimmune disease, chronic pain, or kidney failure.^[1]

Other studies focus on special groups such as children, newborns, adolescents, older adults, healthy volunteers, or patients in the intensive care unit (ICU).^[1] Some trials also focus on people after surgery, such as cardiac surgery, hip surgery, colon surgery, or brain surgery.^[1]

Several studies are aimed at very specific groups, such as people with severe hyponatremia, sickle cell disease, hidradenitis suppurativa, thyroid eye disease, or autism spectrum disorder.^[1]

Trial phases and study size

The collection includes a wide mix of trial phases, with many studies in Phase 3 and several in Phase 2.^[1] There are also smaller early studies in Phase 1 or Phase 1/2, and some low-intervention studies that mainly compare standard care or fluids.^[1]

Enrollment ranges from very small pilot studies with fewer than 20 people to large multicenter trials with thousands of participants.^[1] This shows that Sodium Chloride is used across both early research and larger confirmatory studies.^[1]

Main outcomes being measured

The primary outcomes depend on the condition being studied and the goal of the trial.^[1] Many outcomes are patient-centered, such as pain relief, breathing ability, mobility, recovery scores, or survival.^[1]

• Pain scores are used in many trials, often measured with scales such as the Numeric Rating Scale (NRS) or Visual Analog Scale (VAS).^[1]

• Recovery and function outcomes include walking, mobility scores, quality of recovery questionnaires, and disability scales.^[1]

• Organ injury or function outcomes include kidney injury, lung function, heart function, and brain injury markers.^[1]

• Safety outcomes often include adverse events, serious adverse events, laboratory tests, and vital signs.^[1]

Some studies also use imaging tests, blood markers, or disease-specific scales to measure change over time.^[1]

Selected important trials

The LOTUS trial studies chronic hemodialysis patients and looks at muscle protein synthesis and hemodynamic effects during a one-week treatment period.^[1] Its main outcome is the difference in myofibrillar fractional synthetic rate, which is a measure of muscle protein building.^[1]

The LIVER AKI trial compares human albumin with Sodium Chloride 0.9% in patients with decompensated cirrhosis and acute kidney injury, and it measures kidney recovery without the need for renal replacement therapy.^[1] This is a Phase 3 study with 114 participants.^[1]

The FORE-PAIN trial studies acute traumatic pain in the prehospital setting and compares several pain treatments against controls, including Sodium Chloride used intranasally and intravenously.^[1] Its main outcome is the change in pain score 10 minutes after treatment.^[1]

The CAT-Trial studies painful diabetic neuropathy and measures average pain intensity over 24 weeks.^[1] Sodium Chloride is used as the placebo comparison in this Phase 2 study.^[1]

The TICH-3 trial studies tranexamic acid in stroke caused by intracerebral haemorrhage and uses Sodium Chloride Injection as the comparison treatment.^[1] The main outcome is early death within 7 days after the bleed.^[1]

The LOTUS, LIVER AKI, and TICH-3 studies show how Sodium Chloride is often used to help compare a new treatment against a neutral control in serious hospital conditions.^[1]

What this means for patients

If you see Sodium Chloride in a trial record, it often means the study is comparing a new treatment against a standard neutral option.^[1] This makes it easier to know whether the active treatment really helps.^[1]

These trials do not all study the same illness, so the meaning of participation depends on the condition, age group, and treatment plan in that specific study.^[1] Some trials are short and focus on immediate outcomes, while others follow people for months or even years.^[1]

Table of Contents

• Clinical trial overview
• New onset type 1 diabetes study
• Kidney transplant study
• Liver transplant study
• Main outcomes measured
• Who the studies included

Clinical trial overview

The source data include three Phase 2 clinical trials of Siplizumab.^[1][2][3] All three were interventional studies, which means researchers assigned a treatment and then measured what happened.^[1][2][3] The trials studied different patient groups: people with new onset type 1 diabetes, kidney transplant recipients, and liver transplant recipients.^[1][2][3]

New onset type 1 diabetes study

The STRIDE study was a 12-month, randomized, single-blind, placebo-controlled exposure-response study in adults with new onset type 1 diabetes.^[1] It enrolled 143 people and was completed.^[1] The study tested whether 12 weeks of Siplizumab could help preserve beta-cell function, which is the ability of the pancreas to make insulin.^[1]

The main endpoint was the change from baseline in mean 4-hour stimulated C-peptide AUC after a MMTT at week 52 compared with placebo.^[1] In simple terms, the trial measured how much insulin-making activity remained after treatment.^[1] The study also included comparison treatments listed in the source data, including placebo-related and supportive study medicines.^[1]

Kidney transplant study

Another Phase 2 trial studied Siplizumab in de novo renal transplant recipients, meaning people who had recently received a kidney transplant.^[2] This study was completed and enrolled 46 participants.^[2] It compared Siplizumab with rabbit anti-thymocyte globulin, also called rATG, and followed patients for 12 months after transplant.^[2]

The goal was to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.^[2] Pharmacokinetics means how the body handles a treatment over time, and pharmacodynamics means what the treatment does in the body.^[2] The trial also measured immune markers, CD2 receptor occupancy, estimated glomerular filtration rate (eGFR), and anti-siplizumab antibodies.^[2]

Liver transplant study

A third Phase 2 study looked at whether a Siplizumab-based regimen could induce allogeneic tolerance in deceased donor liver transplant recipients.^[3] This study was suspended and planned to enroll 12 participants.^[3] The condition studied was prevention of liver allograft rejection following tolerance induction.^[3]

The main outcome was the proportion of patients who were free from immunosuppression at month 30 after transplant.^[3] In patient-friendly terms, the study asked whether some people could keep the new liver working without long-term rejection medicine.^[3]

Main outcomes measured

The diabetes study focused on a biological marker of pancreas function, especially stimulated C-peptide after a meal test.^[1] The kidney transplant study focused on safety, lab results, immune effects, kidney function, and antibodies against the study drug.^[2] The liver transplant study focused on whether patients could remain free from immunosuppression after transplant.^[3]

• Safety outcomes included adverse events, serious adverse events, and changes in lab tests and vital signs in the kidney transplant study.^[2]

• Immune outcomes included immunophenotyping, CD2 receptor occupancy, and anti-siplizumab antibodies in the kidney transplant study.^[2]

• Function outcomes included C-peptide in type 1 diabetes and eGFR in kidney transplant recipients.^[1][2]

Who the studies included

The trials focused on specific patient groups rather than the general public.^[1][2][3] One study included adults with recently diagnosed type 1 diabetes.^[1] Another included people who had just received a kidney transplant.^[2] The third included deceased donor liver transplant recipients.^[3]

The source data do not provide the full enrollment rules for each trial, so the exact medical and laboratory requirements are not listed here.^[1][2][3] What is clear is that each trial targeted a different clinical setting where the immune system plays an important role.^[1][2][3]

Table of contents

• Trial overview
• Who is being studied
• What is being measured
• Trial designs and treatment comparisons
• Trial phases and study size
• What these trials mean for patients

Trial overview

These clinical trials are studying Sitagliptin in people with type 2 diabetes mellitus or type 2 diabetes.^[1][2][3] All three studies are Phase 3 interventional trials, which means researchers are testing treatment plans in larger patient groups and comparing outcomes between groups.^[1][2][3]

Who is being studied

The main target population is adults with type 2 diabetes, especially people whose diabetes is not well controlled.^[1] One trial also includes people with cardiovascular autonomic neuropathy, which is nerve damage that can affect heart control.^[2] Another trial focuses on adult participants with type 2 diabetes in a comparison of tirzepatide with intensified conventional care, where Sitagliptin is one of the treatment options listed in the study arms.^[3]

In the first study, the researchers want to see whether pharmacogenetic-guided treatment can improve control of type 2 diabetes compared with optimized standard treatment.^[1] Pharmacogenetic-guided treatment means the choice of treatment is based on a person’s genes.^[1]

What is being measured

The main result in the genetic-treatment study is the proportion of patients who reach a goal HbA1c of 7% or less at Week 24.^[1] HbA1c is a blood test that shows average blood sugar over time.^[1]

In the autonomic neuropathy study, the main outcomes include change in heart rate variability and a measure called the LF:HF ratio, with the goal of seeing a 20% improvement from baseline to the end of treatment at 6 months.^[2] The study also looks at progression of cardiovascular autonomic neuropathy using CART parameters and glucose variability from baseline to the end of treatment.^[2]

In the SURPASS-EARLY study, the main outcome is change from baseline in HbA1c over 104 weeks.^[3] The brief summary says the study aims to show that tirzepatide is non-inferior to intensified conventional care, meaning it works at least as well as the comparison treatment for this measure.^[3]

Trial designs and treatment comparisons

These studies are interventional, so the research team assigns treatment plans rather than only observing usual care.^[1][2][3] The first trial compares pharmacogenetic-guided treatment with optimized standard treatment and includes Sitagliptin among several diabetes medicines listed in the intervention set.^[1]

The second trial compares SGLT-2 inhibitor-based approaches and includes Sitagliptin and other diabetes medicines such as linagliptin, semaglutide, pioglitazone, insulin, canagliflozin, dapagliflozin, and others in the intervention list.^[2] Its objectives are to study possible effects on heart-related nerve function and progression of autonomic neuropathy in people with type 2 diabetes.^[2]

The SURPASS-EARLY study compares tirzepatide with intensified conventional care and lists Sitagliptin among several treatment options used in the study arms.^[3] The trial is designed to compare blood sugar change over time in adults with type 2 diabetes.^[3]

Trial phases and study size

All three studies are in Phase 3, which is an advanced stage of clinical research.^[1][2][3] Phase 3 studies usually involve more people than early studies and are used to learn how well a treatment works in patient groups.^[1][2][3]

The planned enrollment is 504 participants in the genetics-based diabetes study, 80 participants in the autonomic neuropathy study, and 781 participants in the SURPASS-EARLY study.^[1][2][3] This shows that the Sitagliptin-related research includes both smaller focused studies and larger comparative studies.^[1][2][3]

What these trials mean for patients

For patients, these studies are mainly asking whether different ways of choosing or comparing diabetes treatment can improve blood sugar control and related health outcomes.^[1][2][3] The trials focus on people with type 2 diabetes, and one also looks at a nerve-related heart problem that can happen in diabetes.^[2]

Because the studies measure outcomes like HbA1c, heart rate variability, and progression of autonomic neuropathy, they are trying to learn not only whether treatment lowers blood sugar, but also whether it may affect diabetes-related complications.^[1][2][3]

Table of Contents

• Trial overview
• Conditions studied
• What the trials measure
• Trial phases and study designs
• Who may be included
• Patient-relevant points

Trial overview

The trial set includes four interventional studies of Sildenafil Citrate, with one study in Phase 1/2 and three studies in Phase 3.^[1][2][3][4]

The studies are authorised or completed and include small to moderate groups, from 15 participants up to 220 participants.^[1][2][3][4]

Conditions studied

One trial studies digital ulcers in people with systemic sclerosis, which is a long-term disease that can affect the skin and blood vessels.^[1]

Another trial studies peripheral arterial disease in people with intermittent claudication, meaning leg pain that comes on with walking.^[2]

Two studies focus on erectile dysfunction, including one in people with subclinical hypothyroidism and one multicenter study of patient ability to use Sildenafil 100 mg safely on their own.^[3][4]

What the trials measure

The Phase 1/2 study in systemic sclerosis looks at local treatment emergent adverse events, which are unwanted effects seen where the treatment is applied, and at pain reported by the patient using a numeric rating scale from 0 to 10.^[1]

The Phase 3 study in peripheral arterial disease measures the change in absolute claudication distance, the farthest distance a person can walk on a treadmill before leg pain stops them.^[2]

The thyroid and erectile dysfunction study measures changes in questionnaire scores, including IIEF-15, EHS, PGIC, and EDITS, from baseline to three months after treatment.^[3]

The multicenter study in erectile dysfunction mainly checks whether people can use a diagnostic tool to decide safely if Sildenafil 100 mg is appropriate for them; the detailed primary outcome is not public.^[4]

Trial phases and study designs

The systemic sclerosis study is a Phase 1/2 interventional study with escalating dose levels of a topical investigational product on wounds, and it also includes oral Sildenafil Teva as part of the study details.^[1]

The peripheral arterial disease study is a Phase 3, national, multicenter, prospective, randomized, double-blind, placebo-controlled trial.^[2]

The hypothyroidism and erectile dysfunction study is a Phase 3 interventional study that compares study groups over time and follows patients for three months after treatment starts.^[3]

The multicenter erectile dysfunction study is also a Phase 3 interventional study focused on safe independent use of Sildenafil 100 mg.^[4]

Who may be included

The studies are built for different groups of patients, so eligibility depends on the condition being studied.^[1][2][3][4]

• People with systemic sclerosis and digital ulcers may be included in the wound safety study.^[1]

• People with peripheral arterial disease and intermittent claudication may be included in the walking-distance study.^[2]

• People with subclinical hypothyroidism and erectile dysfunction may be included in the hormone and sexual function study.^[3]

• People with erectile dysfunction may be included in the self-use safety study of Sildenafil 100 mg.^[4]

Patient-relevant points

These trials do not study the same problem, so the main goal changes from one study to another.^[1][2][3][4]

Some studies focus on safety, such as local skin tolerability and treatment-emergent adverse events, while others focus on benefit, such as walking farther or improving sexual function scores.^[1][2][3]

The trial names also show that study design matters: one study is placebo-controlled and double-blind, which means neither the participant nor the researcher knows who gets the active treatment during the study period.^[2]

Overall, the research program looks at safety, tolerability, and effectiveness in specific patient groups rather than one single disease area.^[1][2][3][4]

Table of contents

• Trial overview
• Who is being studied
• Study design and phase
• What is being measured
• Trial status and size

Trial overview

The available trial is studying Silibinin in people with Cushing’s disease, a condition linked to excess cortisol.^[1] The study is designed to see whether treatment can decrease or normalize cortisol levels in patients with active disease.^[1]

This is an interventional study, which means researchers give the study treatment and then measure the results.^[1] The brief summary says the goal is to evaluate efficacy, which means how well the treatment works, along with safety in this patient group.^[1]

Who is being studied

The target population is patients with active Cushing’s disease.^[1] The trial data do not list more detailed inclusion or exclusion rules, so the available information only confirms the disease group being studied.^[1]

The study is focused on a small, specific group rather than a broad patient population.^[1] This kind of design is common in early studies that try to find out whether a treatment shows a useful signal before larger trials are done.^[1]

Study design and phase

The trial is Phase 2, which means it is in an intermediate stage of testing.^[1] Phase 2 studies usually look more closely at whether a treatment may work and continue to watch for safety issues in a smaller group of patients.^[1]

The study is described as single arm and open label.^[1] Single arm means there is only one treatment group, and open label means both the study team and the patients know what treatment is being given.^[1]

It is also a dose titration and proof of concept study.^[1] Dose titration means the dose may be adjusted during the study, while proof of concept means the trial is trying to show early signs that the treatment may help.^[1]

What is being measured

The main outcome is efficacy, assessed after 12 weeks of administration.^[1] Researchers will look at several tests that measure cortisol control in different ways.^[1]

• 24-hour urinary free cortisol (UFC): a full-day urine test that shows how much cortisol leaves the body.^[1]
• Late-night salivary cortisol: a saliva test taken at night, when cortisol should normally be low.^[1]
• Low-dose dexamethasone suppression: a test that checks whether cortisol levels drop as expected after a small dose of dexamethasone.^[1]

The trial uses a composite endpoint, which means several results are combined to judge success.^[1] The study looks for patients whose UFC normalizes or drops by at least 50%, patients with high salivary cortisol at baseline whose levels normalize, and patients who did not suppress normally at baseline but later show normal suppression.^[1]

Trial status and size

The trial status is Authorised, meaning it has been approved to move forward.^[1] The planned enrollment is 15 patients, so this is a small study.^[1]

The study title identifies the trial as Silycus®-21 and describes it as a multicenter study.^[1] Multicenter means more than one study site is involved, which can help recruit patients and collect results from different locations.^[1]

Table of contents

• Overview of Simvastatin research
• Conditions being studied
• Trial designs and comparison groups
• Who the studies are for
• Phases and main endpoints
• Key trial highlights
• What the results can mean for patients

Overview of Simvastatin research

These trials study Simvastatin in many different diseases, including pancreatitis, liver disease, stroke, eye disease, and cancer.^[1][2][3] The studies are mostly interventional, which means researchers assign a treatment and then measure what happens.^[1]

The trial phases range from Phase 2 to Phase 4, so the research includes both earlier testing and later studies in larger patient groups.^[1][2]

Conditions being studied

One Phase 3 study tested whether Simvastatin could help prevent recurrent pancreatitis, which means repeated attacks of inflammation of the pancreas.^[1]

Another study looked at people with severe hypertriglyceridemia, a condition with very high blood fat levels, and measured changes in fasting triglycerides after treatment.^[2]

Several trials focus on liver and bile duct disease, including primary sclerosing cholangitis and liver fibrosis linked to alcohol-related liver disease.^[6][5]

Other studies include people with Graves’ ophthalmopathy, spontaneous lobar intracerebral hemorrhage, ischemic stroke or transient ischemic attack, and selected advanced cancers.^[4][3][7][8]

Trial designs and comparison groups

Some studies compare Simvastatin with placebo, which is an inactive treatment used for fair comparison.^[1][5][6]

Some studies compare Simvastatin with no extra treatment or with another medicine, such as diclofenac in Graves’ ophthalmopathy.^[4]

In the intracerebral hemorrhage study, the research compares continuing versus discontinuing statins, and Simvastatin is one of the statins included in the treatment options.^[3]

In the cancer studies, Simvastatin is tested as part of a broader treatment plan, alongside other anti-cancer medicines.^[7][8]

Who the studies are for

Each trial has a specific target group, so not every study is open to every patient.^[1][3]

• The pancreatitis trial enrolled people with recurrent pancreatitis and included 144 participants.^[1]

• The Graves’ ophthalmopathy trial enrolled people with mild to moderate disease and included 102 participants.^[4]

• The liver fibrosis trial studied adults with advanced fibrosis due to alcohol-related liver disease and planned 90 participants.^[5]

• The stroke-related trial focused on frail adults aged 70 and older with a recent ischemic stroke or transient ischemic attack, and it planned 600 participants.^[8]

• The intracerebral hemorrhage trial studied people with spontaneous lobar intracerebral hemorrhage who were already taking a statin, and it planned 1456 participants.^[3]

• The cancer trials focused on patients with advanced or metastatic gastrooesophageal carcinoma or metastatic pancreatic ductal adenocarcinoma.^[7][8]

Phases and main endpoints

The studies include Phase 2, Phase 3, and Phase 4 trials, showing that Simvastatin is being tested in different stages of research.^{[1][2][3][4][5][6][7][8]}

The main outcomes are different in each trial, but they all try to measure whether the treatment changes an important clinical result.^[1]

• In recurrent pancreatitis, the main outcome was recurrence of pancreatitis, meaning whether new attacks happened again.^[1]

• In severe hypertriglyceridemia, the main outcome was the percent change in fasting triglycerides at 26 weeks.^[2]

• In intracerebral hemorrhage, the main efficacy outcome was the risk of recurrent symptomatic bleeding over 24 months, and the safety outcome was major adverse cardiac and cerebrovascular events, often shortened to MACCE.^[3]

• In Graves’ ophthalmopathy, the study measured the clinical activity score and progression to severe disease after 6 months.^[4]

• In liver fibrosis, the key outcome was the change in fibrosis score on the Ishak scale after 24 months.^[5]

• In primary sclerosing cholangitis, the study tracked time to death, liver transplant listing, variceal bleeding, and certain cancers.^[6]

• In the cancer trials, the main outcomes were progression-free survival at 1 year and PFS between two treatment arms.^[7][8]

• In the frail stroke and TIA trial, the outcomes were MACE-free survival and health-related quality of life measured over 2 years.^[8]

Key trial highlights

The recurrent pancreatitis study was a triple-blind, randomized controlled trial, which means the patient, the care team, and the assessors did not know who received which treatment.^[1]

The PSC study was a randomized, double-blind, placebo-controlled multicenter study, which means it used several centers and compared Simvastatin with placebo in a blinded way.^[6]

The liver fibrosis study also used a randomized, double-blind, placebo-controlled design, which is a strong way to compare treatment effects fairly.^[5]

The stroke and TIA study looked at frail older adults, a group that may have different treatment needs and risks than younger people.^[8]

The cancer trials tested Simvastatin together with other medicines, so they are studying it as part of combination treatment rather than alone.^[7][8]

What the results can mean for patients

These trials are trying to answer practical questions about whether Simvastatin can help prevent disease return, slow disease worsening, improve survival, or reduce complications.^[1][3][5][6]

The studies also show that the same medicine can be tested in very different illnesses, so the meaning of the results depends on the exact condition being studied.^[4][7][8]

For patients, the most important point is that each trial has its own rules, its own target group, and its own main outcome, so the results cannot be mixed across all diseases.^{[1][2][3][4][5][6][7][8]}

Table of Contents

• Clinical trial overview
• Phase 3 study in obesity with specific genetic variants
• Phase 2 ROHHAD syndrome study
• What the trials measure
• Who these trials are for

Clinical trial overview

These studies are interventional trials, which means researchers give a study treatment and then measure the results in people.^[1][2]

Both trials are listed as authorised, and both are designed to study Setmelanotide in specific patient groups.^[1][2]

Phase 3 study in obesity with specific genetic variants

The first trial, NCT05093634, is a Phase 3 study in patients with obesity linked to specific genetic variants.^[1]

The study title says it is for patients with obesity with specific genetic variants, and the condition description says it involves improper function of certain messenger materials in the body that control body weight and hunger in people.^[1]

This trial plans to enroll 385 participants.^[1]

The brief summary says the goal is to evaluate the efficacy of Setmelanotide on changes in body weight.^[1]

Phase 2 ROHHAD syndrome study

The second trial, 2024-516753-45-00, is a Phase 2 study called the ROH-SET study.^[2]

It is studying Setmelanotide in people with ROHHAD syndrome, a rare condition named in the trial data.^[2]

This study plans to enroll 5 patients.^[2]

The brief summary says the study aims to evaluate the effect of Setmelanotide on hypothalamic dysfunction in these patients after 16 weeks, 32 weeks, and 52 weeks.^[2]

What the trials measure

The Phase 3 obesity trial uses a primary outcome based on the difference in mean change in body weight from baseline at 52 weeks, compared with placebo.^[1]

The same outcome is also described as percent change from baseline body mass index (BMI), which is a number based on height and weight.^[1]

The ROHHAD study measures changes in overall scores for signs and symptoms of hypothalamic dysfunction at 16, 32, and 52 weeks.^[2]

Hypothalamic dysfunction means problems in the hypothalamus, a part of the brain that helps control hunger, weight, and other body functions.^[2]

Who these trials are for

These trials are not for general obesity or general illness; they focus on people with the specific conditions named in the trial records.^[1][2]

The first study is for patients with obesity and specific genetic variants, while the second is for patients with ROHHAD syndrome.^[1][2]

Together, the studies show that research on Setmelanotide is focused on rare or special patient groups where the main questions are whether the treatment can improve weight-related outcomes or symptoms linked to hypothalamic dysfunction.^[1][2]

Table of Contents

• Trial overview
• Heart failure study
• Type 2 diabetes study
• Outcomes measured in the trials
• Who was studied
• What these trials show about Saxagliptin research

Trial overview

The source data include two clinical trials that mention Saxagliptin as part of the study treatment options.^[1][2] One trial studied people with heart failure with reduced ejection fraction, and the other studied adults with type 2 diabetes.^[1][2] These are interventional studies, which means the researchers assigned treatments and then measured results.^[1][2]

Heart failure study

NCT05989503 was a completed randomized open-label trial in patients with heart failure with reduced ejection fraction.^[1] It enrolled 172 people and was designed to compare two ways of starting treatment: giving angiotensin receptor-neprilysin inhibitor and SGLT2 inhibitor together, or starting SGLT2 inhibitor first and adding the other treatment later.^[1] Saxagliptin appeared in one of the listed drug combinations in the study data.^[1]

The study asked whether the safety of starting the two heart failure treatments at the same time was not worse than the step-by-step approach.^[1] “Not worse than” is called non-inferior, which means the new approach is expected to perform at least as well as the comparison approach within a set margin.^[1]

Type 2 diabetes study

NCT05433584 is an authorised Phase 3 study in adult participants with type 2 diabetes.^[2] It enrolled 781 participants and compared tirzepatide with intensified conventional care.^[2] Saxagliptin was one of the diabetes medicines listed in the intervention set for this trial.^[2]

The main goal was to show that tirzepatide was not worse than intensified conventional care for change in HbA1c from baseline to Week 104.^[2] HbA1c is a blood test that reflects average blood sugar over time, so it is a key measure in diabetes studies.^[2]

Outcomes measured in the trials

The heart failure trial used a composite outcome, which combines several events into one main result.^[1] These events included symptomatic hypotension, hyperkalaemia, hypokalemia, a major drop in eGFR, kidney failure outcomes, increased diuretic dose, intravenous diuretics, heart failure hospitalization, and death from cardiovascular causes during 6 months of follow-up.^[1]

The diabetes trial focused on change in hemoglobin A1c (HbA1c) from the start of the study to Week 104.^[2] This outcome helps show whether a treatment strategy improves long-term blood sugar control.^[2]

Who was studied

The heart failure study involved patients with heart failure with reduced ejection fraction, and the study summary also mentioned HFmrEF, which means heart failure with mildly reduced ejection fraction.^[1] The diabetes study involved adult participants with type 2 diabetes.^[2] In both trials, Saxagliptin was part of the study drug list rather than the only treatment being tested.^[1][2]

What these trials show about Saxagliptin research

Based on the source data, Saxagliptin is being studied in different clinical settings, including heart failure research and diabetes research.^[1][2] The trials focus on practical patient outcomes such as safety events, kidney changes, hospitalisation, death from cardiovascular causes, and HbA1c change.^[1][2] This means the research is aimed at understanding how treatment strategies perform in real patient groups with chronic disease.^[1][2]

Table of Contents

• Clinical trials overview
• Conditions being studied
• Who can take part
• Trial phases and study design
• Main endpoints being measured
• Special and less common research areas
• What these trials may help answer

Clinical trials overview

These studies investigate Semaglutide in many different settings, often as an add-on to standard care or compared with placebo.^[1][2] The trial data include studies in chronic kidney disease, type 2 diabetes, obesity, heart and blood vessel disease, stroke, infertility, liver disease, and several other conditions.^[1][3]

Many trials are designed to see whether Semaglutide improves a main outcome such as blood sugar, body weight, kidney markers, or disease-specific measures.^[2][4] Several studies also look at safety, tolerability, and whether treatment works better than placebo or another active treatment.^[5]

Conditions being studied

Type 2 diabetes is the most common condition in the dataset, and it appears in many adult and pediatric studies.^[2][6] These trials often measure HbA1c, which is a blood test showing average blood sugar over time.^[6]

Obesity is another major research area, including studies in adults, adolescents, children, and people with obesity plus other health problems such as atrial fibrillation, resistant hypertension, heart failure, HIV, or sleep apnea.^[7][8] Several obesity trials measure body weight, BMI, or percent weight loss as the main result.^[7]

Chronic kidney disease is studied in more than one trial, including studies that measure urine albumin-to-creatinine ratio, also called UACR, and estimated kidney function decline.^[1][9] Some kidney studies include people with type 2 diabetes, obesity, or both, while others include chronic kidney disease more broadly.^[1][9]

There are also trials in cardiovascular disease, coronary artery disease, stroke, glaucoma, Alzheimer’s disease, alcohol use disorder, cannabis use disorder, and diabetic foot ulcer.^[3][10] This shows that Semaglutide is being studied far beyond weight and glucose control in the trial program.^[3]

Who can take part

The target populations vary widely across studies.^[2] Some trials include adults with type 2 diabetes, while others focus on children, teenagers, or young adults with obesity.^[6][7]

Several studies include people with extra health risks, such as overweight or obesity plus heart disease, prediabetes, kidney disease, or treatment with antipsychotic medicines.^[8][11] Some trials also have very specific groups, such as people with schizophrenia taking clozapine or olanzapine, women with prior gestational diabetes, or patients after kidney transplant.^[11][12]

A few studies are in children or adolescents with obesity, including those with hypothalamic obesity secondary to craniopharyngioma or obesity linked to antipsychotic treatment.^[7][13] Other studies focus on adults with conditions such as atrial fibrillation, resistant hypertension, or diabetic neuropathy.^[8][14]

Trial phases and study design

Most of the Semaglutide trials in the data are Phase 2 or Phase 3 studies.^[2] Phase 2 trials usually explore whether the treatment may work and continue to watch for safety, while Phase 3 trials are larger and are used to confirm benefit more strongly.^[2]

There are also some Phase 1 studies, such as the oral Semaglutide and dapagliflozin combination study in healthy participants.^[4] In that setting, the main goal is to understand how the medicines behave in the body when given together.^[4]

A few studies are listed as low intervention, which means the research uses limited extra intervention beyond routine care or simple study procedures.^[5] Several trials are randomized, placebo-controlled, or open-label, depending on the question being asked.^[5]

Main endpoints being measured

The most common endpoint in the trial data is change in HbA1c, especially in type 2 diabetes studies.^[6] This endpoint is used to see whether blood sugar control improves over time.^[6]

Weight-related studies often measure change in body weight, BMI, or percent total weight loss.^[7][13] Some studies also use thresholds such as achieving at least 5% weight loss or maintaining BMI below an obesity threshold.^[7][13]

Kidney studies often use UACR or chronic eGFR slope, which is the rate of long-term kidney function change.^[1][9] Heart and blood vessel studies may measure major adverse cardiovascular events, blood pressure, rhythm outcomes, or plaque changes on heart imaging.^[8][10]

Some trials use more specialized endpoints, such as modified Rankin Scale after stroke, good quality blastocysts in IVF, wound closure in diabetic foot ulcer, or gene expression in Alzheimer’s disease.^[14][15] These endpoints show that the studies are asking very different clinical questions, not only weight or glucose questions.^[15]

Special and less common research areas

Several trials explore Semaglutide in areas that are not the usual diabetes or obesity setting.^[10] For example, some studies look at diabetic retinopathy, glaucoma, multiple sclerosis, depression, alcohol use disorder, cannabis use disorder, and chemsex-related drug craving.^[10][16]

Other studies focus on inflammation, endothelial biomarkers, bone turnover, platelet reactivity, liver fat, or hepatic fibrosis.^[3][9][17] These are all biological signs that may help explain whether the treatment changes disease activity, not just symptoms.^[17]

Some trial titles also mention combination approaches, such as CagriSema, IcoSema, or Semaglutide with other medicines like finerenone or dapagliflozin.^[1][4] In these studies, Semaglutide is being tested as part of a broader treatment strategy rather than alone.^[1]

What these trials may help answer

Together, the studies ask where Semaglutide may help most, which patient groups may benefit, and which outcomes improve first.^[2] They also compare different doses, different formulations, and different combinations with other treatments.^[4][7]

The data show that research on Semaglutide is broad and still ongoing, with many authorised trials and several completed studies already available.^[2] The overall focus is on real clinical results that matter to patients, such as blood sugar, weight, kidney health, heart outcomes, and quality of life.^[6][8]

Table of Contents

• Trial overview
• Conditions being studied
• Who can participate
• Trial phases and study designs
• Main endpoints and outcomes
• Key studies using Saline
• What these trials mean for patients

Trial overview

Across the trials provided, Saline is used mainly as a placebo or comparison treatment, not as the main study drug.^[1] The studies are testing many different treatments against Saline in areas such as lung disease, infection, cancer, diabetes, surgery, pain, and immune-related disease.^[2] Most of the trials are interventional, which means researchers assign treatments and then measure what happens.^[3]

Conditions being studied

The trials cover a wide range of conditions. These include chronic obstructive pulmonary disease (COPD), community-acquired pneumonia, respiratory syncytial virus, obesity, early symptomatic Alzheimer’s disease, pancreatic cancer, advanced chronic ischemia with risk of amputation, ovarian cancer, alpha-1 antitrypsin deficiency-associated liver disease, anal fistula, alcohol use disorder, Dupuytren disease, presymptomatic type 1 diabetes, and postoperative pain or blood loss in surgery.^[1][2]

Some studies focus on adults only, such as the RSV vaccine study in immunocompromised patients aged 18 years and older.^[3] Other studies include children, such as the trial in pediatric patients with presymptomatic type 1 diabetes and the study of blood loss in pediatric hip surgery.^[4][5]

Who can participate

Who can join depends on the disease and the study goal. Some trials recruit people with a specific illness, such as COPD, metastatic pancreatic cancer, or alpha-1 antitrypsin deficiency-associated liver disease.^[1][6]

Other studies recruit healthier volunteers or people in a broader group. For example, one trial includes healthy adult participants for propofol injection pain, and another includes healthy volunteers to study liraglutide effects on gut movement and hunger.^[7][8]

Some studies also have special target groups, such as immunocompromised patients, older adults aged 80 years and above, or children with diabetes or surgical needs.^[3][9][4]

Trial phases and study designs

The data include Phase 1, Phase 2, Phase 3, and one Low Intervention study.^[10] Phase 2 trials are common in the list and are used to look more closely at whether a treatment works and to continue safety testing.^[10] Phase 3 trials are also common and usually compare treatments in larger groups to confirm benefit and safety.^[10]

Several trials are randomized, blinded, or placebo controlled. These designs help reduce bias by making comparisons fairer between the active treatment and Saline.^[11]

Main endpoints and outcomes

The primary endpoints vary by study. Some trials measure immune response, such as changes in cytokine production in COPD or interferon-gamma response after vaccination.^[1][12]

Other trials measure clinical outcomes that matter to patients, including overall survival in metastatic pancreatic cancer, progression-free survival in ovarian cancer, days alive and out of hospital in pneumonia, pain scores after surgery, blood loss during surgery, and scar quality after wound healing.^{[6][2][5][13]}

Some studies focus on safety and tolerability, such as the trials in early symptomatic Alzheimer’s disease and alpha-1 antitrypsin deficiency-associated liver disease.^[14][15] Others measure functional change, such as walking distance, ankle/brachial index, sperm concentration, muscle strength, insulin sensitivity, or time until rescue pain medicine is needed.^[16][17][18]

Key studies using Saline

In the COPD vaccine study, Saline is part of a Phase 2 trial that compares vaccination effects on innate immune training, which means the early part of the immune system is being studied for stronger responses after stimulation.^[1] In the pneumonia study, Saline is part of a Phase 2 strategy comparing inhaled levofloxacin with standard intravenous antibiotics, and the main result is days alive and out of hospital at 14 days.^[2]

In the RSV vaccine study, immunocompromised adults receive Saline or the vaccine, and the main endpoint is the fold increase in RSV-A and RSV-B neutralizing titers, which are antibodies that can block the virus.^[3] In the pancreatic cancer trial, Saline is the placebo arm in a large Phase 3 study measuring overall survival.^[6]

In the diabetes and immune studies, Saline is used in trials that look at whether treatment can keep children in stage 1 type 1 diabetes and how many adverse events occur over time.^[4] In the surgery and pain studies, Saline is used to compare pain relief, blood loss, and nerve block effects after procedures.^[5][13][19]

What these trials mean for patients

These studies show that Saline is being used as a comparison treatment across many medical fields.^[1] The goal is not to study Saline itself as a treatment, but to see whether the active study drug or procedure works better than Saline.^[11]

For patients, this means the trial may be looking at whether a vaccine, medicine, block, infusion, or surgery-related treatment improves outcomes compared with a placebo control.^[2][13] The important results vary by condition, but they often include symptoms, recovery, safety, and longer-term health changes.^[14][15]

Table of contents

• Trial overview
• Breast cancer studies
• Bladder and urothelial cancer studies
• Lung cancer studies
• Other cancer studies
• Key endpoints and patient groups
• Safety and biomarker studies

Trial overview

The trial data show that Sacituzumab Govitecan is being tested in many interventional studies, meaning patients receive a study treatment so researchers can measure the results.^[1] The trials range from Phase 1 to Phase 3 and include both completed and authorised studies.^[1]

Most studies focus on advanced, metastatic, or high-risk cancers, but some also study treatment before surgery or after surgery in earlier disease.^[1] Many trials compare Sacituzumab Govitecan with standard care or combine it with other treatments such as pembrolizumab, zimberelimab, domvanalimab, bevacizumab, or platinum chemotherapy.^[1]

Breast cancer studies

Breast cancer is the largest group of studies in the source data.^[1] Trials include triple-negative breast cancer, HR+/HER2-negative breast cancer, HER2-low triple-negative breast cancer, and early breast cancer with a high risk of relapse.^[1]

Several Phase 3 trials compare Sacituzumab Govitecan with treatment of physician’s choice, often using progression-free survival or invasive disease-free survival as the main outcome.^[1] Examples include studies in HR+/HER2− metastatic breast cancer after endocrine therapy, PD-L1 positive metastatic triple-negative breast cancer, and patients with residual invasive disease after surgery and neoadjuvant therapy.^[1]

Some breast cancer trials test combinations rather than Sacituzumab Govitecan alone.^[1] For example, one study tests Sacituzumab Govitecan plus pembrolizumab in low-risk early triple-negative breast cancer, while another tests alternating combinations with trastuzumab deruxtecan in HER2-low triple-negative breast cancer.^[1]

Other studies look at treatment tolerance and side effects in a practical way.^[1] The PRIMED study measures diarrhea and neutropenia, and the SATROPIN study looks at diarrhea during the first two treatment cycles in advanced TNBC or HR(+)/HER2(–) breast cancer.^[1]

Bladder and urothelial cancer studies

Several trials study muscle-invasive bladder cancer and urothelial cancer, including patients who cannot receive cisplatin-based chemotherapy or who refuse cystectomy, which is bladder removal surgery.^[1] These studies often explore bladder-preserving approaches, meaning treatment is aimed at keeping the bladder in place when possible.^[1]

In bladder cancer, the main outcomes include pathological complete response, clinical complete response, and disease-free or event-free survival.^[1] The preSAVE, SURE-02, and perioperative immunotherapy studies all focus on patients with muscle-invasive bladder cancer who are unfit for or unwilling to receive cisplatin-based treatment.^[1]

Urothelial cancer studies also compare Sacituzumab Govitecan with treatment of physician’s choice in locally advanced or metastatic disease.^[1] One Phase 3 study uses overall survival as the main endpoint, while a Phase 2 study measures objective response rate and progression-free survival across different cohorts.^[1]

There is also a Phase 2 study in non-muscle invasive bladder cancer that tests Sacituzumab Govitecan with sasanlimab and measures complete response of high-grade disease at 3 months.^[1]

Lung cancer studies

Lung cancer trials cover both non-small cell lung cancer and extensive-stage small cell lung cancer.^[1] The studies include people with active brain metastases, resectable disease after surgery, advanced disease, and first-line treatment settings.^[1]

In one Phase 2 study, Sacituzumab Govitecan is combined with bevacizumab for brain metastases from non-small cell lung cancer, and the main endpoint is brain objective response rate using RANO-BM criteria.^[1] Another Phase 2 study looks at neoadjuvant treatment before surgery in resectable non-small cell lung cancer and measures pathological complete response.^[1]

Phase 3 trials compare Sacituzumab Govitecan with docetaxel or with treatment of physician’s choice in advanced or metastatic non-small cell lung cancer.^[1] A Phase 3 study in extensive-stage small cell lung cancer compares Sacituzumab Govitecan with standard care and measures objective response rate and overall survival.^[1]

Other cancer studies

Beyond breast, bladder, and lung cancer, the source data include studies in metastatic solid tumors, metastatic esophagogastric adenocarcinoma, thyroid cancer, and endometrial cancer.^[1] These studies show that researchers are testing Sacituzumab Govitecan across different tumor types, not just one cancer.^[1]

A Phase 2 study in metastatic solid tumors measures objective response rate, and a Phase 3 long-term safety study follows patients who are already benefiting from treatment.^[1] The Phase 1/2 esophagogastric study measures overall response rate in metastatic disease.^[1]

In thyroid cancer, the study includes two groups: advanced radioactive-iodine refractory differentiated thyroid carcinoma and advanced anaplastic thyroid carcinoma.^[1] In endometrial cancer, the Phase 3 study compares Sacituzumab Govitecan with treatment of physician’s choice and measures progression-free survival, overall survival, objective response rate, and physical function.^[1]

Key endpoints and patient groups

The most common endpoint is objective response rate, which shows how many patients had tumor shrinkage by standard imaging rules.^[1] Other common endpoints are progression-free survival, overall survival, disease-free survival, event-free survival, and pathological complete response.^[1]

Many trials use RECIST 1.1, a standard method for measuring tumor change on scans, and some use BICR, where outside reviewers check the scans without knowing which treatment was given.^[1] Some studies also use special cancer-specific measures such as RANO-BM for brain metastases and CelTIL score in breast cancer biomarker research.^[1]

Patient groups vary widely, but common patterns are clear.^[1] Many studies include adults with metastatic or locally advanced disease, while others focus on people after surgery, people with high relapse risk, or people who cannot receive cisplatin-based chemotherapy.^[1]

Safety and biomarker studies

Some trials are not only about tumor shrinkage but also about safety and tolerability.^[1] For example, the long-term safety study in metastatic solid tumors measures adverse events, serious adverse events, and laboratory abnormalities.^[1]

The biomarker study in metastatic breast cancer looks at change in CelTIL score between baseline and early treatment samples.^[1] This score combines tumor cellularity and tumor-infiltrating lymphocytes, which are immune cells found inside the tumor, and it is used here as a surrogate of treatment response after one dose.^[1]

Other studies also measure treatment tolerance, such as diarrhea and neutropenia, to better understand how patients handle Sacituzumab Govitecan in real trial settings.^[1]

Table of Contents

• What is Micronized Progesterone?
• Medical Uses
• Administration
• Effectiveness
• Side Effects and Safety
• Ongoing Research

What is Micronized Progesterone?

Micronized progesterone is a form of the hormone progesterone that has been processed to create very small particles. This micronization process makes the hormone easier for your body to absorb and use^[1]. Progesterone is a naturally occurring hormone in the female body, playing a crucial role in the menstrual cycle and maintaining pregnancy.

Medical Uses

Micronized progesterone is primarily used in the field of reproductive medicine. Its main applications include:

• Assisted Reproductive Technology (ART): It’s used to support the luteal phase (the period after ovulation) during fertility treatments^[1].
• Intrauterine Insemination (IUI): Some studies are investigating its use in IUI treatments^[1].
• In Vitro Fertilization (IVF): It’s commonly used in IVF procedures, particularly in frozen embryo transfer cycles^[2].
• Unexplained Infertility: Research is being conducted on its potential benefits for couples with unexplained infertility^[1].

Administration

Micronized progesterone can be administered in different ways:

• Vaginal Use: The most common form is vaginal capsules or gel. This method allows for direct absorption by the uterus^[1][2].
• Oral Use: In some cases, it may be taken orally, although this is less common in fertility treatments^[2].

The dosage and duration of treatment can vary depending on the specific medical condition and treatment protocol. For example, in some IVF protocols, patients might use 200mg three times daily or 400mg twice daily^[2].

Effectiveness

The effectiveness of micronized progesterone in fertility treatments is an active area of research. Some key points include:

• In IVF treatments, progesterone supplementation is considered standard care and has been shown to improve pregnancy outcomes^[1].
• For IUI treatments, research is ongoing to determine if progesterone supplementation can increase live birth rates^[1].
• In frozen embryo transfer cycles, progesterone is crucial for preparing the uterus for embryo implantation^[2].

Side Effects and Safety

Micronized progesterone is generally considered safe for use in fertility treatments. However, like all medications, it can have side effects. Common side effects may include:

• Drowsiness
• Dizziness
• Abdominal pain
• Nausea
• Breast tenderness

It’s important to note that extensive safety data is available from its use in IVF treatments. Both short-term and long-term assessments of offspring health have not revealed any significant risks associated with progesterone use in reproductive medicine^[1].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of micronized progesterone in various fertility treatments:

• The LUMO study is examining whether progesterone support can improve live birth rates in couples undergoing IUI with mild ovarian stimulation^[1].
• Another study is comparing different formulations and dosages of vaginal micronized progesterone in frozen embryo transfer cycles^[2].
• Researchers are also investigating the impact of progesterone levels on pregnancy outcomes in frozen embryo transfer cycles^[2].

These ongoing studies aim to optimize the use of micronized progesterone in various fertility treatments, potentially improving success rates and patient outcomes.

Table of Contents

• What is Prasterone?
• Conditions Treated with Prasterone
• How Prasterone Works
• How Prasterone is Administered
• Effectiveness of Prasterone
• Potential Side Effects
• Ongoing Research

What is Prasterone?

Prasterone, also known as dehydroepiandrosterone (DHEA) or Intrarosa, is a synthetic version of a hormone naturally produced by the human body^[1]. It’s a medication that has been approved by the U.S. Food and Drug Administration (FDA) for treating certain menopausal symptoms^[2]. Prasterone is a type of steroid hormone that can be converted into both estrogen and testosterone in the body.

Conditions Treated with Prasterone

Prasterone is primarily used to treat the following conditions:

• Genitourinary Syndrome of Menopause (GSM): This is a group of symptoms affecting the genital and urinary systems in menopausal women. It includes vaginal dryness, irritation, and pain during sexual intercourse (dyspareunia)^[4].
• Vulvovaginal Atrophy (VVA): This is a condition where the vaginal tissues become thin, dry, and inflamed due to a lack of estrogen^[10].
• Recurrent Urinary Tract Infections (UTIs): Some studies are investigating if prasterone can help prevent recurrent UTIs in postmenopausal women^[2].
• Vaginal Symptoms in Cancer Survivors: Research is being conducted on the use of prasterone for vaginal symptoms in cancer survivors, particularly those who have had breast cancer^[9].

How Prasterone Works

Prasterone works by being converted into estrogen and testosterone in the body. These hormones help to improve the health and function of vaginal tissues. Specifically:

• It increases the number of superficial cells in the vagina, which helps maintain vaginal health^[10].
• It decreases the number of parabasal cells, which are associated with vaginal atrophy^[10].
• It helps to lower vaginal pH, creating a healthier vaginal environment^[10].
• It may improve vaginal lubrication and reduce pain during sexual intercourse^[1].

How Prasterone is Administered

Prasterone is typically administered as a vaginal insert. The most common dosage is 6.5 mg, inserted into the vagina once daily at bedtime^[1][10]. It’s important to follow your doctor’s instructions carefully when using this medication.

Effectiveness of Prasterone

Clinical trials have shown that prasterone can be effective in treating symptoms of GSM and VVA. Some key findings include:

• Improvement in vaginal dryness and pain during intercourse^[1].
• Positive changes in vaginal pH and cell composition^[10].
• Potential improvement in sexual function and quality of life^[10].

Potential Side Effects

While prasterone is generally well-tolerated, it may cause some side effects. These can include:

• Vaginal discharge
• Genital itching or irritation
• Urinary tract infections

It’s important to discuss any side effects with your healthcare provider^[10].

Ongoing Research

Researchers are continuing to study prasterone for various uses:

• Its potential in preventing bone loss in women with lupus who are taking glucocorticoids^[7].
• Its use in breast cancer survivors experiencing vaginal symptoms^[3][9].
• Its effectiveness in preventing recurrent urinary tract infections in postmenopausal women^[2].

As with any medication, it’s crucial to consult with your healthcare provider to determine if prasterone is appropriate for your specific situation.

Table of Contents

• Introduction
• Medical Uses
• Administration and Dosage
• Effectiveness
• Side Effects and Precautions
• Comparisons to Other Medications
• Ongoing Research
• Frequently Asked Questions
• Summary
• Glossary
• References

Introduction

Prednisolone is a corticosteroid medication used to treat various inflammatory and autoimmune conditions. It belongs to a class of drugs known as glucocorticoids, which work by reducing inflammation in the body. Prednisolone is similar to cortisol, a hormone naturally produced by the adrenal glands.^[1]

Medical Uses

Prednisolone is prescribed for several medical conditions, including:

• Asthma: It is used to treat acute exacerbations of asthma in children and adults.^[2]
• COVID-19: Prednisolone has been studied as a treatment for patients with COVID-19 pneumonia requiring oxygen supplementation.^[1]
• Inflammatory conditions: It may be used for various inflammatory and autoimmune disorders.
• Cancer: Prednisolone is sometimes used in combination with other drugs to treat certain types of cancer, such as B-cell lymphomas.^[3]

Administration and Dosage

Prednisolone is typically administered orally in tablet form. The dosage and duration of treatment can vary depending on the condition being treated and the patient’s response. For example:

• For acute asthma exacerbations in children, a study compared a single dose of dexamethasone to multiple doses of prednisolone.^[2]
• In a COVID-19 study, patients received 60 mg per day of prednisolone (40 mg in the morning and 20 mg in the evening) for 10 days.^[1]
• For certain cancer treatments, prednisolone may be given in combination with other drugs, such as oxaliplatin.^[3]

It’s crucial to follow your doctor’s instructions carefully when taking prednisolone, as the dosage may need to be tapered off gradually to avoid withdrawal symptoms.

Effectiveness

Prednisolone has shown effectiveness in various conditions:

• In asthma treatment, its effectiveness is being compared to dexamethasone for acute exacerbations.^[2]
• For COVID-19, researchers are studying its effects on mortality rates in patients requiring oxygen therapy.^[1]
• In cancer treatment, prednisolone combined with other drugs has shown promise in treating certain types of lymphoma.^[3]

Side Effects and Precautions

Like all medications, prednisolone can cause side effects. Common side effects may include:

• Increased appetite and weight gain
• Mood changes
• Difficulty sleeping
• Increased blood sugar levels
• Weakened immune system

Long-term use of prednisolone may lead to more serious side effects, such as osteoporosis, diabetes, and adrenal suppression. Your doctor will monitor you closely for these potential complications.^[1]

Comparisons to Other Medications

Prednisolone is often compared to other corticosteroids:

• Dexamethasone: Studies are comparing the effectiveness of prednisolone to dexamethasone in treating asthma exacerbations and COVID-19.^[2][1]
• Other steroids: Prednisolone may be used as an alternative to other steroids depending on the specific condition and patient factors.

Ongoing Research

Several clinical trials are currently investigating the use of prednisolone:

• Comparing prednisolone to dexamethasone for COVID-19 treatment^[1]
• Evaluating its effectiveness in treating acute asthma exacerbations in children^[2]
• Studying its use in combination with other drugs for cancer treatment^[3]

Frequently Asked Questions

How long does it take for prednisolone to work?

The time it takes for prednisolone to work can vary depending on the condition being treated. For acute conditions like asthma exacerbations, some improvement may be seen within hours to days. For chronic conditions, it may take several days to weeks to see the full effect.

Can I stop taking prednisolone suddenly?

No, you should not stop taking prednisolone suddenly, especially if you’ve been on it for more than a few weeks. Your doctor will provide a tapering schedule to gradually reduce the dose, which helps prevent withdrawal symptoms and allows your body to adjust.

Are there any foods or medications I should avoid while taking prednisolone?

You should avoid grapefruit and grapefruit juice as they can interact with prednisolone. Always inform your doctor about all medications, supplements, and herbal products you’re taking, as some may interact with prednisolone. Your doctor may also recommend limiting salt intake and ensuring adequate calcium and vitamin D to help prevent side effects.

Summary

Glossary

• Corticosteroid – A class of steroid hormones produced in the adrenal cortex or made synthetically, used to reduce inflammation and suppress the immune system.
• Glucocorticoid – A type of corticosteroid that affects metabolism and has anti-inflammatory effects.
• Exacerbation – A worsening or increase in severity of a disease or its symptoms.
• Adrenal suppression – A condition where the adrenal glands do not produce adequate amounts of steroid hormones, particularly cortisol.

Trial Sources

• [1]: https://clinicaltrials.gov/study/NCT04765371
• [2]: https://clinicaltrials.gov/study/NCT05850143
• [3]: https://clinicaltrials.gov/study/NCT01068392

Table of Contents

• What is Placebo?
• How Placebo is Used in Clinical Trials
• Medical Conditions Studied with Placebo
• How Placebo is Administered
• Safety and Side Effects
• Effectiveness of Placebo

What is Placebo?

A placebo is an inactive substance or treatment that looks identical to the real medication being tested in a clinical trial^[1]. It’s often referred to as a “sugar pill” because it contains no active ingredients and has no direct therapeutic effect^[1]. Placebos are crucial in medical research to help determine the true effects of new treatments.

How Placebo is Used in Clinical Trials

In clinical trials, placebos are used as a comparison to the active treatment being studied. Patients are typically randomly assigned to receive either the real treatment or the placebo, without knowing which they are getting. This helps researchers determine if the actual medication is more effective than no treatment at all^[2][3].

For example, in a study on a new diabetes medication, some patients received the real drug while others got a placebo that looked identical^[4]. This allows researchers to compare the effects and see if the real drug truly makes a difference.

Medical Conditions Studied with Placebo

Placebos are used in research for a wide variety of medical conditions. Some examples from the provided studies include:

• Restless Legs Syndrome (RLS): A condition causing uncomfortable sensations in the legs and an urge to move them^[5]
• Bacterial Vaginosis: An infection causing abnormal vaginal discharge^[3]
• Diabetic Peripheral Neuropathic Pain: Nerve pain caused by diabetes^[1]
• Osteoarthritis: Joint pain and stiffness typically affecting older adults^[6]
• Cocaine Dependence: Addiction to the drug cocaine^[7]

How Placebo is Administered

Placebos are designed to mimic the real treatment being studied. They can be given in various forms, including:

• Oral tablets or capsules^[4]
• Vaginal tablets^[3]
• Creams applied to the skin^[8]
• Injections^[9]

The dosing schedule for placebos also matches that of the real treatment. For instance, in one study, participants took the placebo orally twice a day for up to 51 days^[1].

Safety and Side Effects

Since placebos don’t contain active ingredients, they generally don’t cause direct side effects. However, people taking placebos may experience what’s known as the “placebo effect” – feeling better simply because they believe they’re receiving treatment^[5].

In clinical trials, researchers carefully monitor all participants for any adverse events (negative health effects), regardless of whether they’re receiving the real treatment or placebo^[1]. This helps ensure patient safety and provides valuable information about the treatment being studied.

Effectiveness of Placebo

While placebos don’t have direct therapeutic effects, the placebo effect can be powerful. In some studies, a significant number of patients taking placebos report improvements in their symptoms^[5].

For example, in a study on restless legs syndrome, researchers looked at how many patients taking the placebo reported feeling “much improved” or “very much improved” after treatment^[5]. This helps them understand how much of the real treatment’s effect might be due to patients’ expectations rather than the medication itself.

It’s important to note that the use of placebos in research doesn’t mean that the conditions being studied aren’t real or serious. Rather, placebos help ensure that new treatments are truly effective before they’re approved for widespread use.

Table of Contents

• What is Pioglitazone?
• Conditions Treated with Pioglitazone
• How Pioglitazone Works
• Dosage and Administration
• Potential Side Effects
• Ongoing Research and Potential New Uses

What is Pioglitazone?

Pioglitazone is a medication primarily used to treat type 2 diabetes. It belongs to a class of drugs called thiazolidinediones, which are also known as “insulin sensitizers”^[1]. Pioglitazone is often sold under the brand name Actos^[2]. This medication helps to control blood sugar levels in people with diabetes by making the body more sensitive to its own insulin, a hormone that regulates blood sugar.

Conditions Treated with Pioglitazone

While pioglitazone is primarily used for treating type 2 diabetes, research has shown that it may be beneficial for other conditions as well:

• Polycystic Ovary Syndrome (PCOS): Pioglitazone has been studied for its potential to improve menstrual irregularities and reduce excess male hormones (hyperandrogenism) in women with PCOS^[1].
• Cancer Prevention: Some studies are investigating whether pioglitazone could help prevent certain types of cancer, such as head and neck cancer in patients with oral leukoplakia (white patches in the mouth that can sometimes develop into cancer)^[3].
• Brain Protection: Researchers are exploring if pioglitazone could help protect the brain from radiation-induced cognitive dysfunction in patients receiving radiation therapy for brain tumors^[4].
• Sepsis: There is ongoing research to determine if pioglitazone could help reduce inflammation in patients with severe sepsis and septic shock^[5].

How Pioglitazone Works

Pioglitazone works by activating a specific protein in your cells called peroxisome proliferator-activated receptor-gamma (PPARγ)^[1]. This protein helps your body:

• Use insulin more effectively, which helps control blood sugar levels
• Reduce inflammation throughout the body
• Regulate fat storage and metabolism

By improving how your body responds to insulin, pioglitazone can help lower blood sugar levels in people with type 2 diabetes. Its anti-inflammatory effects are also being studied for potential benefits in other conditions.

Dosage and Administration

Pioglitazone is typically taken orally (by mouth) once daily. The dosage can vary depending on the condition being treated and the individual patient’s needs. Some common dosages seen in clinical trials include:

• For diabetes: 30 mg or 45 mg once daily^[6]
• For PCOS: 30 mg once daily, potentially increased to 45 mg after 2 months if needed^[1]
• For research in other conditions: dosages may vary, but often start at lower doses like 15 mg or 22.5 mg daily^[2]

Always follow your doctor’s instructions regarding dosage and administration. Do not adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, pioglitazone can cause side effects. Some potential side effects include:

• Fluid retention and weight gain: This is one of the most common side effects. It may lead to swelling (edema) in some patients^[7].
• Increased risk of heart failure: Especially in patients with existing heart problems^[7].
• Bone fractures: There may be an increased risk, particularly in women^[7].
• Liver problems: Rarely, pioglitazone can affect liver function^[7].
• Bladder cancer: Some studies have suggested a possible increased risk, although this is rare^[7].
• Low blood sugar (hypoglycemia): Especially when used with other diabetes medications^[7].

It’s important to discuss potential side effects with your doctor and report any unusual symptoms you experience while taking pioglitazone.

Ongoing Research and Potential New Uses

Researchers are continually studying pioglitazone to understand its full potential. Some areas of ongoing research include:

• Brain health: Studies are looking at how pioglitazone affects brain blood flow and cognitive function in elderly individuals^[2].
• Cancer prevention: Researchers are investigating if pioglitazone could help prevent certain types of cancer, particularly in high-risk individuals^[3].
• Inflammatory conditions: The anti-inflammatory properties of pioglitazone are being studied in conditions like sepsis^[5].
• Combination therapies: Studies are exploring how pioglitazone works when combined with other medications for diabetes and other conditions^[8].

While these research areas are promising, it’s important to remember that pioglitazone is currently only approved for use in type 2 diabetes. Any other uses should be discussed with and supervised by a healthcare professional.

Table of Contents

• What is PENTIXAFOR?
• How Does PENTIXAFOR Work?
• What Conditions is PENTIXAFOR Being Studied For?
• The PENTIXAFOR Imaging Procedure
• Potential Benefits of PENTIXAFOR Imaging
• Current Research and Clinical Trials
• Safety and Side Effects

What is PENTIXAFOR?

PENTIXAFOR is a new imaging agent being studied for use in diagnosing and evaluating certain types of cancer^[1]. It is not a treatment drug, but rather a substance that helps doctors see cancer cells more clearly during a special type of scan called PET (Positron Emission Tomography). PENTIXAFOR is also known by its chemical name, [68Ga]Ga-Pentixafor^[10].

How Does PENTIXAFOR Work?

PENTIXAFOR works by targeting a specific protein called CXCR4, which is found in high amounts on the surface of many cancer cells^[1]. When PENTIXAFOR is injected into the body, it attaches to these CXCR4 proteins. The PENTIXAFOR is labeled with a small amount of radioactive material (gallium-68) that can be detected by a PET scanner. This allows doctors to see where the cancer cells are located in the body^[2].

What Conditions is PENTIXAFOR Being Studied For?

PENTIXAFOR is being investigated for use in several types of cancer and blood disorders, including:

• Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow^[9]
• Lymphoma: Cancer that starts in cells of the lymph system^[2]
• Neuroendocrine Tumors: Rare tumors that can occur in various parts of the body^[1]
• Thymoma: A tumor of the thymus gland^[6]
• Leukemia: Cancer of blood-forming tissues^[7]
• Adrenal Gland Disorders: Such as conditions causing excess hormone production^[8]

The PENTIXAFOR Imaging Procedure

The PENTIXAFOR imaging procedure typically involves the following steps:

1. A small amount of PENTIXAFOR is injected into a vein, usually in the arm^[2].
2. The patient waits for about 60 minutes to allow the PENTIXAFOR to circulate through the body and attach to cancer cells^[10].
3. The patient lies still on a bed that moves through a PET scanner, which takes images of the inside of the body^[1].
4. The scan usually takes between 45 to 90 minutes^[1].

Potential Benefits of PENTIXAFOR Imaging

Researchers are studying PENTIXAFOR because it may offer several advantages over current imaging techniques:

• It may be more sensitive in detecting certain types of cancer, especially those that don’t show up well on standard PET scans using a different tracer called FDG^[11].
• It could help doctors more accurately determine how far a cancer has spread (staging)^[12].
• It might be useful in detecting minimal residual disease (small amounts of cancer cells remaining after treatment)^[12].
• It could potentially help predict how a patient will respond to certain treatments^[10].

Current Research and Clinical Trials

PENTIXAFOR is still considered an experimental imaging agent. It is being studied in clinical trials to determine its effectiveness and safety. These trials are comparing PENTIXAFOR PET scans to other imaging techniques and evaluating how well it can detect different types of cancer^[9][11].

Some studies are also looking at how PENTIXAFOR imaging results compare to other tests, such as bone marrow biopsies or blood tests for minimal residual disease^[10].

Safety and Side Effects

As PENTIXAFOR is still being studied, information about its safety and potential side effects is limited. However, the amount of radioactive material used is very small, and the radiation exposure is generally considered low^[1].

In clinical trials, patients are monitored for any adverse reactions for about an hour after receiving the PENTIXAFOR injection^[10]. Vital signs such as heart rate, blood pressure, and breathing rate are checked before and after the procedure^[10].

It’s important to note that PENTIXAFOR is not a treatment itself, but a diagnostic tool. It does not treat cancer or cause any therapeutic effects^[1].